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Isolation is the gift, 
all the others are a test of your endurance,  
of how much you really want to do it 
and you’ll do it. 
despite rejection  
and the worst odds 
and it will be better  
than anything else you can imagine. 
 
If you’re going to try, 
go all the way. 
there is no other feeling like that. 
you will be alone with the gods 
and the nights will flame with fire. 
 
do it, do it, do it. 
do it. 
all the way 
all the way. 
 
 
- Charles Bukowski 
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Abstract 
 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
caused by mutations in the huntingtin gene (HTT). These mutations expand the CAG 
triplet repeat region resulting in an unstable polyglutamine stretch (polyQ) in the N-
terminal domain of the protein. Epigenetic marks such as histone methylation are 
significantly altered in HD patients as well as HD cellular and organismal models. 
Specifically, H3K9 trimethylation (H3K9me3) is markedly increased in HD patients and 
HD mouse models, which correlates with transcriptional repression.  In this study we 
make use of induced pluripotent stem cells (iPSCs) as they present a unique tool for 
disease modeling and hold a great promise for regenerative medicine. We use iPSCs from 
patients with HD (HD-iPSCs) and induce their differentiation into neuronal HD-IPSCs 
(HD-NPCs) to identify mechanisms that can correct HD disease-related changes.  
Therefore, in a first step we asked for the normal function of HTT.  We show for the first 
time that HTT interacts with chromatin factor ATF7IP and its specific H3K9 
methyltransferase SETDB1. In addition, we observed that loss of HTT increased the levels 
of ATF7IP and global H3K9me3 in hESCs. In pluripotent stem cells the levels of 
heterochromatin-associated histone modifications such as H3K9me3 are usually reduced 
which indicates that HTT regulates H3K9me3 levels in hESCs. Next, we show that 
knockdown of ATF7IP in HD-iPSCs and their neuronal differentiated counterparts results 
in a decrease of H3K9me3. As with HTT, upon knockdown of huntingtin interacting 
protein 2 (UBE2K) we observed increased H3K9me3 in hESCs, probably through the 
histone methyltransferase regulator JARID2, an interactor of UBE2K found firstly in this 
study. However, UBE2K KD came with a dramatic dysfunctional phenotype towards the 
neural differentiation abilities of the cells. Therefore, UBE2K and the normal function of 
HTT could be required within a bigger complex of epigenetic regulators to maintain the 
H3K9me3 landscape of hESCs and HD-iPSCs. 
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Zusammenfassung 
 
Die Huntington-Krankheit (HD) ist eine autosomal dominante neurodegenerative 
Erkrankung, die durch Mutationen im Huntingtin-Gen (HTT) verursacht wird. Diese 
Mutationen erweitern den CAG-Triplett-Wiederholungsbereich, was zu einem instabilen 
Polyglutamin-Stretch (polyQ) in der N-terminalen Domäne des Proteins führt. 
Epigenetische Marker wie die Histonmethylierung sind bei HD-Patienten sowie bei 
zellulären und organismischen HD-Modellen signifikant verändert. Insbesondere die 
H3K9-Trimethylierung (H3K9me3) ist bei HD-Patienten und HD-Mausmodellen deutlich 
erhöht, was mit einer transkriptionellen Repression korreliert.  In dieser Studie 
verwenden wir induzierte pluripotente Stammzellen (iPSCs), da sie ein einzigartiges 
Werkzeug zur Modellierung von Krankheiten darstellen und ein großes Potenzial für die 
regenerative Medizin bieten. Wir verwenden iPSCs von Patienten mit HD (HD-iPSCs) und 
induzieren deren Differenzierung in neuronale HD-IPSCs (HD-NPCs), um Mechanismen 
zu identifizieren, die krankheitsbedingte Veränderungen bei HD korrigieren können. 
Daher haben wir in einem ersten Schritt nach der normalen Funktion von HTT gefragt.  
Wir zeigen hier zum ersten Mal, dass HTT mit dem Chromatinfaktor ATF7IP und seiner 
spezifischen H3K9-Methyltransferase SETDB1 interagiert. Darüber hinaus beobachteten 
wir, dass der Verlust von HTT das Ausmaß von ATF7IP und globalem H3K9me3 in hESCs 
erhöhte. In pluripotenten Stammzellen sind die Werte von Heterochromatin-assoziierten 
Histon-Modifikationen wie H3K9me3 in der Regel reduziert, was darauf hindeutet, dass 
HTT den Gehalt an H3K9me3 in hESCs reguliert. Als nächstes zeigen wir, dass der 
Knockdown von ATF7IP bei HD-iPSCs und ihren neuronal differenzierten Gegenstücken 
zu einem Rückgang von H3K9me3 führt. Wie bei HTT beobachteten wir beim Knockdown 
des mit Huntingtin interagierenden Proteins 2 (UBE2K) einen Anstieg von H3K9me3 in 
hESCs, vermutlich mit Hilfe des Histon-Methyltransferase-Regulators JARID2, einem 
Interaktor von UBE2K, der erstmals in dieser Studie gefunden wurde. Der UBE2K KD 
hatte jedoch einen drastisch dysfunktionalen Phänotyp in Bezug auf die neuronalen 
Differenzierungsfähigkeiten der Zellen. Daher könnten UBE2K und die normale Funktion 
von HTT in einem größeren Komplex epigenetischer Regulatoren erforderlich sein, um 
den H3K9me3-Spiegel aus hESCs und HD-iPSCs zu erhalten. 
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1 Introduction 
 
1.1 Huntington's disease  
 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
caused by mutations in the huntingtin gene (HTT). The characteristic symptoms of the HD 
which entail abnormal movements (chorea), cognitive decline (dementia) and psychosis, 
manifest usually from the age of 35 to 501,2. The disease leads to death approximately 20 
years after onset of first symptoms3. The mutations of the HTT gene expand a CAG triplet 
repeat region in exon 1 resulting in an unstable polyglutamine stretch (polyQ) in the N-
terminal domain of the protein. In its wild-type form, HTT contains 6-35 glutamine 
residues. However, in individuals affected by HD, it contains greater than 35 polyQ 
repeats4. Although HTT is ubiquitously expressed5,6, mHTT particularly leads to neuronal 
dysfunction and death in many brain regions with the striatum undergoing the greatest 
neurodegeneration7. Extensive data and the dominant inheritance pattern of HD indicate 
that gain-of-function of mHTT is toxic and triggers neurodegeneration4,8,9, especially in 
the striatal medium-sized spiny neurons10. However, growing evidence suggests that loss 
of normal HTT function also contributes to HD5,6. For instance, loss of wild-type HTT 
induces HD-related changes such as progressive neurodegeneration and motor 
dysfunction or hastens these changes in human and mouse HD models11–15. Moreover, 
ectopic expression of wild-type HTT improves brain cell survival and ameliorates the 
deleterious effects of the mutant protein12, 16–22 . 
 
1.2 Huntingtin  
 
The HTT gene is well conserved from flies to mammals and has no sequence 
homology with other proteins. It probably appeared millions of years ago, before the 
seperation of the protostoma (origin of insects) and deuterostoma (mammals) 
branches5,6. HTT is a completely soluble high-molecular-weight protein of 348 kDa (3,144 
amino acids) and is ubiquitously expressed.  
In HTT protein structure, the region of highest interest in HD-research is the 
expandable polyQ region. The polyQ tract starts at the eighteenth amino acid and contains 
up to 34 glutamine residues in healthy individuals. Moreover, there are also other 
proteins such as transcription factors which contain a polyQ region23. A study showed 
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that the polyQ tract forms a three-dimensional protein motif that forms interactions with 
polar residues (Polar Zipper) and thus might have its physiological function in the binding 
of these proteins24. A region found only in higher vertebrates is the polyproline stretch, 
which is assumed to aid in the solubility of the HTT25. The protein also contains several 
HEAT domains of ∼40 amino acids which enable protein-protein interactions26,27. In HTT 
around 37 HEAT repeats were discovered28, of which three key clusters were identified27. 
 
Further downstream, a carboxy (C)-terminal nuclear export signal (NES) sequence 
and a nuclear localization signal (NLS) are localized. The NLS was found to be less active 
than the NES. This indicates that this location of the protein is responsible for molecular 
transportation from the nucleus to the cytoplasm29. In addition, the widespread 
distribution of HTT within the cell nucleus and other cell compartments supports this 
idea. In more detail studies showed, that HTT functions as a nuclear export protein 
through its interaction with the nuclear pore protein TPR (translocated promoter region). 
In support of this role was the observation that HTT accumulates in the nucleus, when the 
amino acids of the interacting region were deleted30. 
The three protease cleavage sites split the protein into normal and mutant HTT 
(mHTT) fragments31–33, which are found in the nucleus and cytoplasm34–38. Caspase and 
calpain family members have a proteolytic role for mHTT36,38–40. HTT has several 
consensus caspase38 and calpain cleavage sites40, also known as cysteine proteases. 
Calpains, however are Ca2+-dependant intracellular cysteine proteases41. It should be 
noted that excessive glutamatergic signaling and impaired excessive Ca2+ influx in the 
brain striatum, lead to mitochondrial dysfunction and cell death42. This pathway is an 
activator of cysteine proteases like caspases and calpains41. Caspase cleavage is activated 
by proteolytic processes such as apoptosis41 and is a common process, as this event was 
observed in control human brains as well as in HD-brains in the early stage of disease, or 
in WT and HD transgenic mouse brains before neurodegeneration commenced38. It is 
known that HTT is a substrate of calpain to induce cleavage. The activation of calpain 
cleavage is initiated by programmed cell death in the cell43 and also targets other polyQ 
containing proteins causing neurodegenerative diseases32. 
 
HTT fragments resulting from caspase-and calpain proteolysis tend to accumulate 
in the nucleus. This is because mHTT cleavage only releases the polyQ containing N-
terminal fragments, which are prone for aggregation and are toxic in the cell32,39. 
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Interestingly, reducing the activity of calpain and caspase cleavage sites decreased the 
cleavage of the mHTT and thus delayed the onset of the disease33,39,44.  
 
The post-translational modifications of HTT include sumoylation, ubiquitination, 
phosphorylation and palmitoylation. The amino (N)-terminal lysines K6, K9 and K15 get 
either ubiquitinated45 or sumoylated25. Further, the serines 421 and 434 get 
phosphorylated, which influences the cleavage and toxicity of mHTT. Studies showed that 
phosphorylation of these serines is reduced in the HD46–49. The palmytoylation of 
huntintin is done by the HTT-interacting protein 14 (HIP14) which is a palmitoyl 
transferase50. Proteins which are palmitoylated are known to regulate components which 
control vesicle trafficking and thus support the role of HTT in vesicle trafficking50,51. 
 
HTT is capable of binding to its numerous interactors in both its wild-type and 
mutant form52,53. This feature indicates that it has a flexible structure which adapts its 
conformation and function depending on the current subcellular location, state of 
maturation or cell type54,52,28,55,56. For example, the expanded polyQ region is capable of 
changing the three-dimensional structure of the HTT, making it accessible to different 
interacting proteins24,52. The protein epitopes presented by HTT are supposedly 
differentially accessible by the same antibodies, depending on the intracellular 
compartment the HTT is found in57,58.  
 
In humans and rodents HTT is found mainly in the cytoplasm51, with the highest 
levels in the CNS neurons and the testes59–61. Within the cell it is found in several 
organelles including the nucleus, endoplasmic reticulum and golgi complex51,62–65 . HTT 
has many binding partners and the most important ones are involved in transcriptional 
regulation, intracellular trafficking and cytoskeletal organization. Interestingly many of 
the known interactors of HTT have functions in endocytosis and only a few in exocytosis66. 
HTT has been associated with synaptic vesicles51,62, microtubule-based axonal transport, 
endosomal structures and clathrin-coated vesicles63. Taken together, an important 
function of normal HTT seems to lie in membrane trafficking. HTT also facilitates tri-
methylation of H3K27 by the chromatin regulator polycomb repressive complex 2 (PRC2) 
in mouse embryonic stem cells (mESCs), a mechanism further induced by a gain of 
function of the mHTT67. 
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1.3 The role of HTT in development and cell differentiation.  
 
Remarkably, conditional knockout of Htt in mice at embryonic day 14.5 causes 
progressive neurodegeneration that mimics HD phenotypes11. At earlier stages, complete 
depletion of HTT results in severe neural developmental defects and embryonic 
lethality68–70, providing a link between normal function of HTT and development. Mice 
with reduced levels of HTT to below 50% bypass the lethality phenotype but display 
aberrant brain development, suggesting a role of HTT in neurogenesis71. Loss of HTT 
during embryonic neurogenesis decreases the pool of cortical progenitors by accelerating 
their differentiation, a process that results in altered cell fate decisions72. In vitro, neural 
progenitor cells (NPCs) derived from Htt-/- mouse ESCs (mESCs) can be terminally 
differentiated into neurons. However, a study demonstrated that their neuronal 
differentiation efficiency is altered as they tend to give rise to more astrocytes compared 
with wild-type NPCs73. Another study finds even earlier phenotypes such as decreased 
self-renewal, increased cell death and alterations in the lineage potential of NPCs derived 
from Htt-/- mESCs74. Although patients with HD and disease mouse models do not exhibit 
striking developmental phenotypes as HTT knockout models5,71,75,76, cumulative evidence 
indicates developmental deficits in HD mouse models and human pathological 
specimens77–80. For instance, polyQ-expanded HTT induces deficits such as impairment in 
the maintenance of striatal neural stem cells and their specification into medium spiny 
neurons80. Furthermore, both HD patients and mouse models exhibit abnormalities in 
brain morphology and synaptic plasticity before the onset of apparent clinical deficits81–
87. It is also known that HTT improves brain cell survival when it is 
overexpressed18,19,21,22,88. 
 
Research showed that HTT has anti-apoptotic effects, both in vitro19,46,89 and in 
vivo17,88 and protects neurons from excitotoxicity in vivo18. These cell-autonomous 
activities originate from the 548 amino acid terminus (N548) of the HTT protein and 
affect neuronal and non-neuronal cells5. An important function of HTT, which is more 
specific to neurons, is the stimulation of brain-derived neurotrophic factor (BDNF) gene 
transcription. It controls the transcription of the gene by inhibiting the silencer element 
“Repressor element 1” (RE1), or “neuron-restrictive silencer element” (NRSE) on the 
BDNF gene promoter21,22, but also of many other genes which carry these silencer 
elements on their promoters. Besides, HTT is responsible for vesicle and BDNF transport, 
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and the regulation of many processes important to normal brain function, such as fast 
axonal trafficking and synaptic transmission5. When mESCs are genetically modified to 
express polyQ-expanded HTT, they maintain their ability to form NPCs. Upon neuronal 
induction, these cells exhibit a higher percentage of neuronal cell death resulting in a 
decreased percentage of neurons remaining at the end of the differentiation process73. 
Although HD-iPSCs from patients and control iPSCs differentiate into NPCs with 
indistinguishable efficiency, HD-NPCs exhibit abnormalities in cytoskeleton, cell adhesion 
and energetics90. Moreover, HD-NPCs present HD-related transcriptional dysregulation in 
genes involved in cell cycle, signaling, axonal guidance and neuronal development90. HD-
NPCs can be terminally differentiated into neurons that exhibit HD-related changes such 
as alterations in calcium homeostasis, electrophysiology, increased vulnerability to 
excitotoxic stressors and cumulative risk of death over time37. Altogether, these findings 
suggest a role of HTT during development whereas its potential dysregulation by mutant 
polyQ could predispose neurons to degeneration and/or other HD-related changes.  
 
 
1.4 Stem cells and their epigenetic landscape 
 
Given the role of HTT in neuronal development, it is of importance to understand 
its regulatory function in embryonic stem cells (ESCs). Human embryonic stem cells 
(hESCs) are derived from the inner cell mass of blastocysts. These cells replicate 
continuously in the absence of senescence while maintaining their ability to differentiate 
into all cell lineages91,92 .  
 
One essential mechanism in order to maintain stem cell identity is the maintenance 
of the proteome via the ubiquitin-proteasome system (UPS). The UPS administers 
selective protein degradation by covalent ligation to a 76-amino-acid-residue protein 
called ubiquitin93. There are numerous targets for the ubiquitin-mediated degradation, 
such as regulatory proteins, which control cell-cycle progression, signal transduction or 
transcriptional regulation among many other important processes93,94. Importantly, the 
UPS was found to coordinate pluripotency in embryonic stem cells and induced 
pluripotent stem cells95. Furthermore, ubiquitin-mediated degradation is known for its 
important role in development and programmed cell death93,94. In eukaryotic cells the 
degradation of proteins is usually accomplished through a multi-step ubiquitination 
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process, which includes the reversible covalent conjugation of polypeptides to its 
substrates in an adenosine triphosphate (ATP)-dependent manner. The synthesized 
polyubiquitin chain, linked mostly through lysine 48 of the ubiquitin peptide, is 
recognized and hydrolyzed into short peptides by the 26S (2000 kDa) proteasome. The 
released ubiquitin molecules are then re-used94,96. As a first step a ubiquitin polypeptide 
is adenylated by the ubiquitin activating enzyme (E1). Next a sulfhydryl group of the 
proteasome is added to build a E1–ubiquitin thiolester and the activated ubiquitin is 
directed to one of the many E2 enzymes via transthiolation. As a last step the protein 
ubitquitination is catalyzed by the E2 enzyme, either alone or with an E3 ligase97.  
 
Extensive progress has been made in characterizing the transcriptional network 
that regulates self-renewal and differentiation of hESCs, including transcription factors 
such as OCT4, NANOG and SOX298. Likewise, epigenetic modifiers regulate hESC 
pluripotency and cell reprogramming99,100. In comparison with their differentiated 
counterparts, hESCs have a unique nuclear and chromatin architecture such as fewer 
condensed heterochromatin foci101. This less compact chromatin pattern facilitates its 
dynamic reorganization during development. The chromatin state is modulated by DNA 
methylation and dynamic assembly/disassembly of histones as well as other related 
proteins. hESCs have a specific signature of DNA methylation, a key epigenetic regulatory 
mechanism to modulate gene expression102. Whereas differentiated cells exhibit more 
DNA methylation genome-wide suggesting a less active chromatin structure, hESCs have 
less DNA methylation reflecting a more open and dynamic architecture of 
chromatin103,104. Furthermore, ESCs exhibit a specific histone modification pattern, 
named bivalent domains, consisting of large regions of H3K27me3 repressive marks 
harboring smaller regions of H3K4me4 activation marks105. These bivalent domains could 
have a function to silence developmental genes in ESC while keep them poised for 
activation. Moreover, the levels of heterochromatin-associated histone modifications 
such as H3K9me3 are usually reduced whereas the levels of transcriptional activations 
marks such as acetylated histones are generally increased in hESCs106,107. A complex 
network of proteins such as the polycomb repressive complex 2 (PRC2) regulates histone 
modifications. In ESCs, PRC2 forms a complex with the Jumonji and ARID-domain-
containing protein (JARID2) maintaining H3K27me3 chromatin marks108. Although the 
histone code has a critical role in chromatin and gene regulation, the molecular 
mechanisms that modulate the unique chromatin pattern of hESCs remain largely 
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unknown. Given their specific chromatin structure signature, hESCs could provide a 
different paradigm to discover novel epigenetic regulatory mechanisms and their impact 
on differentiation. Moreover, a better understanding of chromatin regulation in hESCs 
could lead to novel pathways to facilitate cell reprogramming of somatic cells. Thus, a firm 
understanding of the epigenetic machinery involved in hESC self-renewal and cell fate 
decisions is central importance.  
 
Importantly, NPCs and neurons derived from HD-iPSCs show transcriptional 
changes consistent with those observed in HD brain, including dysregulation of genes 
involved in cell cycle, cell signaling, neuronal development and axonal guidance90. 
Transcriptional dysregulation is a prominent defect observed in postmortem HD brains 
and distinct HD mouse models6,109. Epigenetic marks such as DNA methylation and post-
translational modifications of histone proteins are significantly altered in HD patients as 
well as HD cellular and organismal models110. Thus, epigenetic alterations could 
contribute to transcriptional abnormalities in HD110. Among these epigenetic changes, 
H3K9 trimethylation (H3K9me3) is robustly increased in HD patients and HD mouse 
models111–114. H3K9 hypermethylation is accompanied by upregulation of its specific 
methyltransferase SETDB1113. SETDB1 activity is regulated by ATF7IP. H3K9me3 is 
associated with heterochromatin and correlates with transcriptional repression115.   
 
ATF7IP regulates chromatin formation by binding and directing transcriptional 
factors to the general transcriptional machinery. Depending on the subcellular conditions 
the protein can operate either as an activator or a repressor116–119. In particular, ATF7IP 
has an effect on histone methylation that is essential for chromatin structure and function. 
In particular, the histone methyltransferase (HMTase) activity of Histone-lysine N-
methyltransferase SETDB1 (SETDB1) depends on the assistance of ATF7IP. It triggers the 
transformation of the dimethyl (H3K9me2) to the trimethyl state (H3K9me3) by 
increasing the turnover rate of the reaction, both in vitro and in vivo.  
 To conclude, pluripotent stem cells are an invaluable resource for disease 
modeling and hold a great promise for regenerative medicine, in particular for 
understanding disease mechanisms in neurodegenerative diseases. The observations 
raise an intriguing question: does HTT regulate H3K9me3 levels in pluripotent stem cells 
via the described ATF7IP/SETDB mechanisms? In this thesis, I use human embryonic 
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stem cells (hESCs) and induced pluripotent stem cells (iPSCs) from HD-patients (HD-
iPSCs) to identify epigenetic mechanisms that can correct disease-related changes. 
 
 
1.5 The role of the HTT interacting protein 2 “UBE2K“ 
 
As described above, HTT has many binding partners. One of the first described 
interactors of HTT is the HTT interacting protein 2 (UBE2K or HIP2).  UBE2K is a member 
of the E2 ubiquitin ligase family, which consists of approximately 35 enzymes. E2 ligases 
are essential for the proper functioning of the UPS. Briefly, as an E2 ubiquitin conjugating 
enzyme, UBE2K accepts ubiquitin from the E1 complex and catalyzes its covalent 
attachment to other protein lysine residues via E3 ubiquitin ligases120. Although it is 
known that HTT is ubiquitinated it is not known whether UBE2K targets HTT for 
ubiquitination45.  The 22 kDa protein was discovered as an HTT interactor in a yeast two-
hybrid system study. They found that the human protein consisted of an amino acid 
sequence identical to the bovine ubiquitin-conjugating enzyme (E2-25K), and was further 
described to interact with the amino terminus of the HD protein. Specifically, by using an 
anti-E2-25K polyclonal antibody, a protein slightly bigger than UBE2K was bound and 
exclusively located in HD-affected brain regions45. Further studies showed that UBE2K is 
highly expressed in the frontal cortex and striatum of the brain121.  
 
Like HTT, mRNA expression of the mouse UBE2K homolog (mHIP-2) was shown to 
increase with maturation of neurons, and thus, both are likely to have an impact brain 
development. Also, both HTT and mHIP-2 have the same regional mRNA distribution 
pattern. This indicates a common transcriptional regulation for the two proteins, although 
the mHIP-2 expression started earlier than HTT expression122. 
 
A different study using the yeast two-hybrid system identified UBE2K as one of six E2’s 
interacting with the human heterodimeric RING E3 BRCA1-BARD1 ubiquitin-protein 
ligase complex. UBE2K binds to the BRCA1 RING and mediates the synthesis of Lys63- or 
Lys48-linked polyubiquitin chains on BRCA1123. Moreover, UBE2K could be a involved in 
the pathogenesis of Alzheimer’s disease, by suppressing the proteasome activity and 
causing aggregation of ubiquitin conjugates in neurons, also referred to as amyloid-β 
peptide (Aβ) neurotoxicity124,125. It is known that protein aggregation is a hallmark of 
 17 
neurodegenerative diseases such as HD and that the protein modification molecule 
ubiquitin aids in the localization and degradation of toxic aggregates125.  Another study 
looked at the subcellular localization in neuronally differentiated cells and showed 
positive staining of UBE2K primarily co-aggregates with expanded polyglutamine 
proteins in apoptotic cells. This finding is in line with staining experiments in postmortem 
brain cells from HD patients126. 
 
UBE2K might be involved also in other biological systems, for instance in the 
ubiquitination of proteins in atherosclerosis, caused by macrophages and human 
monocytes. The aggregated low-density lipoprotein (agLDL) hinders the apoptosis of 
atherosclerosis causing, lipid-bearing macrophages, leading to unwanted foam cell 
formation. One of the genes induced by agLDL, termed low-density lipoprotein (LDL)-
inducible gene (LIG) contained the coding sequence for UBE2K. This anti-apoptotic 
function could be revoked in the presence of proteasome inhibitor127. In mice, the 
SUMOylation of UBE2K ortholog E2-25K protects against neuronal cell death during 
oxidative stress. By SUMOylation the proteasome activity of subunit S5a is downregulated 
means of protection against cell death. UBE2K also interacts with a regulatory protein 
named cyclin B1, which is involved in mitosis. It thereby ameliorates cyclin B1-induced 
apoptosis by regulating the stability of the cyclin B1 protein121. In the model organism C. 
elegans knockdown of RNAi mediated ubiquitin-conjugating enzymes (UBC’s) showed 
severe effects on aggregates. Especially, after the knockdown of ubc-1, ubc-13, or uev-1, 
aggregates could not be localized by the ubiquitin molecule, suggesting that these ubc 
enzymes are necessary for aggregate ubiquitination125. 
 
 It is currently unclear if UBE2K plays a role in the abundant modifications of 
histone lysine residues during epigenetic changes (methylation, acetylation, 
ubiquitylation) in stem cell differentiation. Therefore, the aim of this thesis was to dissect 
the role of Huntington and UBE2K on the epigenetic landscape and on the function of 
neuronal differentiation in hESCs. 
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2 Material and Methods 
2.1 Materials 
 
Table 1: Cell lines 
 
NAME DESCRIPTION SOURCE 
H9 (WA09) hESC WiCell Research Institute 
H1 (WA01) hESC WiCell Research Institute 
HFIB2-IPS4 iPSCs control (Park, Zhao et al. 2008) 128 
HD-IPSC#1 iPSC Q71 (Park, Arora et al. 2008) 129 
ND42242 iPSC Q21 control Coriell Institute 
ND36997 iPSC Q33 control Coriell Institute 
ND42229 HD iPSC Q71 Coriell Institute 
ND36999 HD iPSC Q180 Coriell Institute 
 
 
Table 2: hESC Culture and chemicals 
 
NAME 
 
COMPANY 
1X PBS, W/O CA/MG Life technologies 
2-MERCAPTOETHANOL Sigma 
2-PROPANOL Sigma 
2,4,6-TRICHLORANISOL (TCA) Sigma 
4X LAEMMLI SAMPLE BUFFER BioRad 
4X500ML ACRYLAMIDE/BIS SOLUTION 
37,5:1 
Serva 
5-BROMO-2`DEOXYURIDINE Sigma 
10X DPBS Life technologies 
10X TRIS BUFFERED SALINE BioRad 
10X TRIS/BORIC ACID/EDTA BioRad 
10X TRIS/GLYCINE BioRad 
10X TRIS/GLYCINE/SDS BioRad 
ACCUTASE 100 ML Stem Cell Technologies 
ACETON Sigma 
ADENOSINE 5′-TRIPHOSPHATE 
DISODIUM SALT HYDRATE 
Sigma 
AGAROSE, ULTRAPURE 500G Life technologies 
ALBUMINE FROM BOVINE SERUM Sigma 
AMMONIUM BICARBONATE Roche 
AMMONIUMSULFATE Carl Roth 
AMMONIUM PERSULFATE, 10 G BioRad 
ASCORBIC ACID Sigma 
APROTININ FROM BOVINE LUNG Sigma 
B27 SERUMFREE SUPPLEMENT Life technologies 
BDNF  Peprotech 
BFGF  Joint Protein Central 
CHLOROFORM Sigma 
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CITRIC ACID Sigma 
CF-1 MEFS Amsbio 
CLARITY WESTERN ECL SUBSTRATE BioRad 
COLLAGENASE TYPE IV Life technologies 
CYCLOHEXIMIDE Sigma 
D-(+)-GALACTOSE Sigma 
D-(+)-GLUCOSE Sigma 
DAPI (4,6 DIAMINIDO-2-PHENYLIN) Life technologies 
DEPC-TREATED WATER Life technologies 
DEOXYCHOLIC ACID SODIUM Sigma 
DIBUTYRYL-CYCLIC AMP  Sigma 
DL-DITHIOTHREITOL (DTT) Sigma 
DISPASE Stem Cell Technologies 
DMEM, NO GLUCOSE Life technologies 
DMEM/F-12, HEPES Life technologies 
DMEM/F:12 Life technologies 
DMSO Sigma 
DNA POLYMERASE I  Promega 
DYNABEADS PROTEIN G  ThermoFisher 
EDTA Sigma (Roche Prot.) 
EDTA SOLUTION PH 8,0 VWR 
EGTA Sigma 
EPIDERMAL GROWTH FACTOR Sigma 
ETHANOL 99,5% (DENAT. 1% MEK) VWR 
ETHANOL PURE Sigma 
FBS SOUTH AMERICAN HI Life technologies 
FGF-BASIC HUMAN 1000ΜG Peprotech 
FLUORSAVE REAGENT Merck 
FORMALDEHYDE, 10%, METHANOL 
FREE 
Polyscience 
FORMIC ACID Sigma 
GDNF HUMAN Peprotech 
GELATIN FROM PORCINE SKIN Sigma 
GELTREX LDEV Life technologies 
GENTLE DISSOCIATION REAGENT  Stem Cell Technologies 
GLACIAL ACETIC ACID Sigma 
GLUTAMAX 1 Life technologies 
GLYCEROL, 500 ML LifeTechnologies 
GLYCOGEN Life technologies 
GLYCIN Sigma 
HEPES STERIL 1M PH7.3 VWR 
HI-MARK PRE-STAINED PROTEIN 
LADDER 
Life technologies 
HOECHST LifeTechnologies 
HYDROCHLORIC ACID Sigma 
HYDROGEN PEROXIDE 30% Sigma 
IGEPAL CA-630 Sigma 
IMMOBILON WESTERN CHEMILUM HRP 
SUBSTRATE 
Merck 
INCUWATER-CLEAN VWR 
 20 
IODACETAMIDE (IAA) Sigma 
ISOPROPANOL Sigma 
KALIUMHYDROGENPHOSPAT Roth 
KNOCKOUT SERUM REPLACEMENT  ThermoFisher Scientific 
LAMININ Life technologies 
L-ASCORBIC ACID Sigma 
L-GLUTAMINE Joint Protein Central 
LITHIUMCHLORID (LICL) Sigma 
MAGNESIUM CHLORIDE HEXAHYDRATE Millipore 
METHANOL Sigma 
MTESR1  Stem Cell Technologies 
MOWIOL Carl Roth 
N2 SUPPLEMENT ThermoFisher Scientific 
N-LAUROYLSARCOSINE Sigma 
N-ETHYLMALEIMIDE Sigma 
NEUROBASAL MEDIUM Life technologies 
NITROCELLULOSE MEMBRANE 45ΜM Bio-Rad 
N,N-DIMETHYLFORMAMID Sigma 
NON-ESSENTIAL AMINO ACIDS Life technologies 
NONFAT-DRIED MILK FROM BOVINE Sigma 
NP-40 Sigma 
PBS, W/O CA/MG (10X) Life technologies 
PENICILIN/STREPTOMYCIN Life technologies 
PHENOL CHLOROFORM BD 
PHENOL:CHLOROFORM:ISOAMYL 
ALCOHOL 
Sigma-Aldrich 
PHENYLMETHYLSULFONYL FLUORIDE 
(PMSF) 
Sigma 
POLY-L-ORNITHINE HYDROBROMIDE Sigma 
PONCEAU S SOLUTION Sigma 
POTASSIUM ACETATE Sigma 
POTASSIUM CHLORIDE Sigma 
POTASSIUM DIHYDROGEN PHOSPHATE Fisher 
POTASSIUM HYDROGEN PHOSPHATE 
DIBASIC 
ALFA 
POTASSIUM HYDROXIDE ALFA 
PRECISION PLUS PROTEIN DUAL COLOR 
STANDARDS, 5X 
BioRad 
PROTEIN A BEADS  Miltenyi 
PROTEIN ASSAY DYE REAGENT 
CONCENTRATE, 450 ML 
BioRad 
PROTEINASE K, RECOMBINANT Sigma 
PROTEASE INHIBITOR (25 TABL.) Sigma 
PUROMYCIN 10X1ML Life technologies 
PVDF.45UM IMMOBILON Merck 
RANDOM PRIMERS ThermoFisher Scientific 
RESOLVING GEL BUFFER, 1.5 M TRIS-
HCL, PH 8.8, 1 
BioRad 
RNABEE Tel-Test Inc. 
RNASE A Peqlab 
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RNASE H Peqlab 
ROCK INHIBITOR (Y-27632 
DIHYDROCHLORIDE) 
Abcam 
SDS- SODIUM DODECYL SULFATE Sigma 
SDS SOLUTION 20% (W/V) BioRad 
SODIUM 4-PHENYLBUTYRATE Sigma 
SODIUM ACETATE, ANHYDROUS VWR 
SODIUM ACETYL-L-CYSTEINE Sigma 
SODIUM AZIDE Sigma 
SODIUM BICARBONATE Life technologies 
SODIUM CHLORIDE VWR 
SODIUM DEOXYCHOLATE Sigma 
SODIUM FLUORIDE Sigma 
SODIUM HYDROGEN PHOSPHATE 
DIBASIC 
ALFA 
SODIUM HYPOCHLORITE SOLUTION Sigma 
SODIUM ORTHOVANADATE Sigma 
SODIUM SELENITE Sigma 
SUCROSE Sigma 
STACKING GEL BUFFER BioRad 
STEMDIFF DEFINITIVE ENDODERM KIT  Stem Cell Technologies 
STEMDIFF NEURAL INDUCTION 
MEDIUM 
Stem Cell Technologies 
STEMDIFF NEURAL PROGENITOR 
MEDIUM 
Stemcell Technologies 
TEMED BioRad 
TETRAETHYLAMMONIUM 
BOROHYDRIDE (TEAB) 
Sigma 
TRIS 1M PH 7,5 VWR 
TRIS–HCL Sigma, Roth 
TRITON X-100 Sigma 
TRYPSIN 0.25 EDTA Life technologies 
TWEEN® 20 Biochemica 
ULTRAPURE DNASE/RNASE-FREE 
WATER 
Life technologies 
UREA Roche 
 
 
Table 3: Antibodies & chemicals protein biochemistry 
 
ANTIBODY COMPANY 
ALEXA FLUOR 488 GOAT ANTI 
MOUSE IGG (H+L) 
Life technologies 
ALEXA FLUOR 488 GOAT ANTI 
RABBIT IGG (H+L) 
Life technologies 
ALEXA FLUOR 546 GOAT ANTI 
MOUSE IGM 
Life technologies 
ANTI-ATF7IP  Proteintech 1:500 WB 
ANTI-BETA ACTIN Abcam 1:1,000 WB 
ANTI-H3  Cell Signaling Technologies, 1:10,000 WB 
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ANTI-H3K9ME3  Abcam, 1:1000 WB 
ANTI-HTT  Cell Signaling Technologies, 1:1000 WB 
ANTI-HTT-POLYQ (MW1-S)  from DSHB, 1:500 WB 
ANTI-MAP2 Sigma 1:500 WB 
ANTI-NESTIN  Stem Cell Technologies, 1:1,000  
ANTI-OCT4  Stem Cell Technologies, 1:500 
ANTI-PAX6  Stem Cell Technologies, 1:200 
ANTI-SETDB1  Abcam, 1:500  
ANTI-SOX2  Abcam, 1:1,000 
HRP AP DONKEY ANTI-MOUSE IGG 
(H+L) 
Jackson Immuno Research 
HRP AP DONKEY ANTI-RABBIT IGG 
(H+L) 
Jackson Immuno Research 
STEMDIFF NEURAL PROGENITOR 
ANTIBODYPANEL 
Stemcell Technologies 
 
ANTI-FLAG Sigma 
 
 
Table 4: Lentiviral vectors. in pLKO.1-puro vector Mission shRNA 
 
NAME COMPANY 
LENTIVIRUS (LV)-NON-TARGETING SHRNA 
CONTROL 
Sigma 
LV-HTT SHRNA#1 (TRCN0000322961) Sigma 
LV-HTT SHRNA#2 (TRCN0000019869) Sigma 
LV- ATF7IP SHRNA#1(TRCN0000020827) Sigma 
LV-ATF7IP SHRNA#2 (TRCN0000338504) Sigma 
LV-UBE2K SHRNA#1 (TRCN0000237896) Sigma 
LV-UBE2K SHRNA#2 (TRCN0000237893) Sigma  
 
 
Table 5: Kits 
 
NAME COMPANY 
ADDGENE FIRELAB KIT Addgene 
FUGENE Promega 
NORMOCIN InvivoGen 
PIERCE BCA PROETIN ASSAY KIT Fisher Sientific 
QIAGEN LONGRANGE 2STEP RT-PCR KIT Quiagen 
QIAGEN-TIP 20 Quiagen 
QUANTA Q FLEX REVERSE TRANSCRIPTION KIT VWR 
RNA BEE Gentaur 
SSOADVANCED SYBR GREEN SUPERMIX Bio-Rad 
TMTSIXPLEX ISOBARIC MASS TAG KIT PROTOCOL Thermo Scientific 
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Table 6: qRT-PCR Primers 
 
GENE FORWARD REVERSE 
ACTB CTGGCACCCAGCACAATG CCGATCCACACGGAGTACTTG 
GAPDH GCACCGTCAAGGCTGAGAAC GGATCTCGCTCCTGGAAGATG 
HTT F  TGCAGCCCTGTCCTTTCAAG CTCCAAGGCTTCTTCTTCTCCTAA 
ATF7IP F  CACTGAACTACAGGCCAAGATAGC GGTGGATGTTCATGTCTTTTCTTAAG 
OCT4 F GGAGGAAGCTGACAACAATGAAA GGCCTGCACGAGGGTTT 
NANOG F  AAATCTAAGAGGTGGCAGAAAAACA GCCTTCTGCGTCACACCATT 
DPPA4 F  CTGGTGCCAACAATTGAAGCT AGGCACACAGGCGCTTATATG 
SOX2 F  TGCGAGCGCTGCACAT TCATGAGCGTCTTGGTTTTCC 
PAX6 F  CATACCAAGCGTGTCATCAATAAAC TGCGCCCATCTGTTGCT 
NESTIN F TGAAGGGCAATCACAACAGG TGACCCCAACATGACCTCTG 
MAP2  AAAGAAGCTCAACATAAAGACCAGACT GTGGAGAAGGAGGCAGATTAGC 
FGF5 F  ACGAGGAGTTTTCAGCAACAAAT TTGGCACTTGCATGGAGTTTT 
MSX1 F  CTCCGCAAACACAAGACGAAC CACATGGGCCGTGTAGAGTC 
ALB F  TGAGGTTGCTCATCGGTTTAAA GCAATCAACACCAAGGCTTTG 
GATA4 F  TCCGTGTCCCAGACGTTCTC GAGAGGACAGGGTGGATGGA 
GATA6 F  AGCGCGTGCCTTCATCA GTGGTAGTTGTGGTGTGACAGTTG 
ASCL2 CGCGCGATCACATTCTGTAA TCGCAGATTTCGCCAGTTG 
GBX1 TTTCTTCCCTCTGTTCGCCT GGAAGGCCGAAAGAAAGCAA 
SMC1B GAGTGAGGGCAGAGAACAGG CCTTCATCTCAGGGGCTCC 
ADGRB1 TTGTGATGGTGTTGGTGCTG ACCATCATCACCACCACCAT 
UBE2K CGCGGTGCAGCGAATC TTGCTCGTCTCCTCGCTCTT 
ZFP42 CCTGCAGGCGGAAATAGAAC GCACACATAGCCATCACATAAGG 
AADC GGACCCCACTTACCTGAAGCA CTGCCAATGCCGGTAGTCA 
TH+ TGTCCACGCTGTACTGGTTCAC CGGCACCATAGGCCTTCA 
TUJ1 GGCCAAGTTCTGGGAAGTCA CGAGTCGCCCACGTAGTTG 
SYN CGCAGTGGAAGCGCTACA CCCACCACCTCAATGATGTG 
NEUN ACCAACGGCTGGAAGCTAAA GCATAGAATTCAGGCCCGTAGA 
GABAR TGCGAAGGACAGTGGAGAAGT GAGGGCGGATGGAGATATCC 
NEFL GCTATGCAGGACACGATCAACA TTAGGTATCGTGCCATTTCACTCTT 
NEFM CAGGACCTCCTCAACGTCAAG CCTGCAAATGTGCTAAATCTAGTCTCT 
SOX1 GCTGACACCAGACTTGGGTT GTGCTTGGACCTGCCTTACT 
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Table 7: Electrical devices 
 
DEVICE COMPANY 
ACHRO-PLAN 10X ZEISS 
AGILENT 2100  Bioanalyzer 
AXIOCAM 506 MONO ZEISS 
AXIO ZOOM.V16 ZEISS 
BINDER CB-150 BINDER GmbH 
BIORUPTOR SONICATOR Diagenode 
C1000 TOUCH THERMAL CYCLER Bio-Rad 
CFC384 REAL-TIME SYSTEM Bio-Rad 
DRI-BLOCK DB-2D Techne 
EC-PLAN-NEOFLUAR 20X-40X ZEISS 
ENSPIRE MULTIMODE PLATE READER 
2300 
Perkin Elmer 
EPPENDORF 5430R, 5424, 5810R Eppendorf 
FUSION SOLO Vilber Lourmat 
HANNA INSTRUMENTS HI3220 HANNA Instruments GmbH 
HEIDOLPH UNIMAX 1010 Heidolph Instruments GmbH 
ILLUMINA HISEQ 4000 SEQUENCER Illumina 
IMAGER. Z1 ZEISS 
INCUCELL MMM MMM group 
MINI TRANS-BLOT CELL Bio-Rad 
MINI-PROTEAN TGX, 10% ;10W; 10 Bio-Rad 
MINI-PROTEAN TETRA CELL Bio-Rad 
MINI-SUB CELL GT SYSTEM W/ 7X7 Bio-Rad 
MINI-TRANS-BLOT MODULE Bio-Rad 
NANODROP 8000 ThermoFisher Scientific 
POWERPAC BASIC HC Bio-Rad 
PRECISA XB4200C Precisa Gravimetrics AG 
S1000 THERMAL CYCLER Bio-Rad 
SCANLAF CLASS 2 MARS Labogene 
SHAKING PLATFORM RM S-30V M. Zipper GmbH 
STEREO DISCOVERY.V8 ZEISS 
THERMOMIXER COMFORT Eppendorf 
VTX-3000L MIXER UZUSIO LMS Co., Ltd 
ZEISS APOTOME .2 ZEISS 
ZEN IMAGING SOFTWARE ZEISS 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 hESC culture and differentiation 
hESC/iPSC lines were maintained on Geltrex (ThermoFisher Scientific) coated 
plates using mTeSR1 (Stem Cell Technologies). Undifferentiated colonies were passaged 
using dispase (2 mg ml-1), and colonies were scraped with a glass pipette. Genetic identity 
of H9 and H1 hESCs was assessed by short tandem repeat (STR) analysis using the 
Promega PowerPlex 21 system (Promega Corporation) by Eurofins Genomics (Germany). 
The H9 and H1 hESC lines used in this study match exactly the known STR profile of these 
cells across the 8 STR loci analyzed. All the cell lines used in this study were tested for 
mycoplasma contamination at least once every three weeks and no mycoplasma 
contamination was detected. Research involving hESC lines was performed with approval 
of the German Federal competent authority (Robert Koch Institute). 
Neural differentiation of hESCs/iPSCs was performed following the monolayer 
culture method with STEMdiff Neural Induction Medium (Stem Cell Technologies) based 
on Chambers, S. M. et al.130.  
The hESCs were rinsed once with PBS and 1 ml Gentle Dissociation Reagent (Stem 
Cell Technologies) was added. After 10 min at 37°C the pluripotent stem cells were gently 
dislodged using a p1000 pipette and 2ml of Dulbecco’s Modified Eagle Medium (DMEM)-
F12 + 10 μM ROCK inhibitor (Abcam) were added. Accordingly, cells were centrifuged at 
300g for 5 min in a 15 ml falcon. Cells were re-suspended on STEMdiff Neural Induction 
Medium + 10 μM ROCK inhibitor and plated on polyornithine (15 μg ml-1)/laminin (10 μg 
ml-1)-coated plates (200,000 cells cm−2). Following this protocol, we were able to induce 
neural differentiation of H9, H1 and iPSCs. 
For pan-neuronal differentiation, NPCs were dissociated with 1 ml Accutase (Stem 
Cell Technologies) and plated on polyornithine (15 μg ml−1)/laminin (10 μg ml−1)-coated 
plates in neuronal differentiation medium consisting of Dulbecco’s Modified Eagle 
Medium (DMEM)/F12, B27, N2 (ThermoFisher Scientific), 1 μg ml−1 laminin 
(ThermoFisher Scientific), 20 ng ml−1 GDNF (Peprotech), 20 ng ml−1 BDNF (Peprotech), 
200 nM ascorbic acid (Sigma) and 1 mM dibutyryl-cyclic AMP (Sigma). Cells were 
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differentiated for 1 month (otherwise the time is indicated in the respective figures), with 
weekly feeding of neuronal differentiation medium.  
Endoderm differentiation of H9 hESCs was performed using STEMdiff Definitive 
Endoderm Kit (Stem Cell Technologies). 
2.2.1.2 Lentiviral infection of hESCs.  
Transient infection experiments for shRNA screen were performed as follows. 
hESC colonies growing on Geltrex were incubated with mTesR1 medium containing 10 
μM ROCK inhibitor (Abcam) for 2 h. For de-attaching the cells 1 l Accutase per well were 
added for 5 min at 37°C and centrifuged at 300g for 5 min in a 15 ml falcon. Cells were 
then re-suspended with a p1000 pipette in order to produce single cells. Hundred 
thousand cells per well were seeded on Geltrex coated W12 plates and incubated with 
mTesR1 medium containing 10 μM ROCK inhibitor. The next day cells were infected with 
5 μl of concentrated lentivirus. Plates were centrifuged at 800g for 1 h at 30 °C. Cells were 
fed with fresh media on day 2 after infection to remove virus. On day 3 cells were selected 
for lentiviral integration using 2 μg ml−1 puromycin (ThermoFisher Scientific). Cells were 
then collected for qPCR experiments after 4–6 days of infection. 
For UBE2K shRNA experiments we generated stable transfected hESCs. To obtain 
shRNA stable lines, hESC colonies growing on Geltrex coated plates were incubated with 
mTesR1 medium containing 10 μM ROCK inhibitor for 1 h. For dislodging the cells 1 ml 
Accutase per well were added for 5 min at 37°C and centrifuged at 300g for 5 min in a 15 
ml falcon. Cells were then re-suspended with a p1000 pipette to obtain single cells. Fifty 
thousand cells were infected with 20 μl of concentrated lentivirus in the presence of 10 
μM ROCK inhibitor for 1 h. Cell suspension was centrifuged to remove virus, pipetted up 
and down to obtain individual cells, and plated on a feeder layer of mitotically inactive 
mouse embryonic fibroblasts (MEFs) in hESC media (DMEM/F12, 20% knockout serum 
replacement (ThermoFisher Scientific), 0.1 mM non-essential amino acids, 1 mM L-
glutamine, β-mercaptoethanol and 10 ng ml−1 bFGF (Joint Protein Central)) supplemented 
with 10 μM ROCK inhibitor. After a few days in culture, allowing small hESC colonies to 
grow, knockdown cells were selected by 1 μg ml−1 puromycin treatment for 2 days. 
Colonies were then passaged onto Geltrex coated plates to establish new hESC lines.  
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2.2.1.3 Immunocytochemistry.  
Human cells were fixed with paraformaldehyde (4% in PBS) for 15 min, followed 
by permeabilization (0.2% Triton X-100 in PBS for 10 min) and blocking (3% BSA in 0.2% 
Triton X-100 in PBS for 10 min). Human cells were incubated in primary antibody for 2 h 
at room temperature (Rabbit anti-HTT (Cell Signaling Technologies #5656, 1:100), Mouse 
anti-OCT4 (Stem Cell Technologies, #60093, 1:200), Rabbit anti-PAX6 (Stem Cell 
Technologies, #60094, 1:300), Mouse anti-MAP2 (Sigma, #1406, 1:500), Rabbit anti-
H3K9me3 (Abcam #8898, 1:500), Mouse anti-SETDB1 (Abcam, #107225, 1:200) and 
Rabbit anti-ATF7IP (Proteintech #14699-1-AP, 1:500)). Then, cells were washed with 
0.2% Triton-X/PBS and incubated with secondary antibody (Alexa Fluor 488 goat anti-
mouse (ThermoFisher Scientific, A-11029, 1:500), Alexa Fluor 568 goat anti-rabbit 
(ThermoFisher Scientific, A-11011, 1:500), and 2 μg ml−1 Hoechst 33342 (Life 
Technologies, #1656104) for 1 h at room temperature. The cover slips were washed with 
0.2% Triton-X/PBS and distilled water before mounting. 
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2.2.2 Gene expression analysis 
 
RNA isolation and quantitative RT–PCR. For human cell samples, total RNA was 
extracted using RNAbee (Tel-Test Inc.). cDNA was generated using qScript Flex cDNA 
synthesis kit (Quantabio). SybrGreen real-time qPCR experiments were performed with a 
1:20 dilution of cDNA using a CFC384 Real-Time System (Bio-Rad) following the 
manufacturer’s instructions. Data were analyzed with the comparative 2ΔΔCt method 
using the geometric mean of ACTB and GAPDH as housekeeping genes. 
 
2.2.3 Biochemistry 
2.2.3.1 Sample preparation for quantitative proteomics and analysis 
For the comparison between Non-targeting control and HTT KD H9 hESCs, we 
performed label-free quantitative (LFQ) proteomics. Cells were collected in urea buffer (8 
M urea, 50 mM ammonium bicarbonate and 1x complete protease inhibitor mix with 
EDTA (Roche)), homogenized with a syringe and cleared using centrifugation (16,000g, 
20 min). Supernatants were reduced (1 mM DTT, 30 min), alkylated (5 mM iodoacetamide 
(IAA), 45 min) and digested with trypsin at a 1:100 w/w ratio after diluting urea 
concentration to 2 M. The next day samples were cleared (16,000g, 20 min) and 
supernatant was acidified. Peptides were cleaned up using stage tip extraction131. The 
liquid chromatography tandem mass spectrometry (LC-MS/MS) equipment consisted out 
of an EASY nLC 1000 coupled to the quadruple based QExactive instrument (Thermo 
Scientific) via a nano-spray electroionization source. Peptides were separated on an in-
house packed 50 cm column (1.9 μm C18 beads, Dr.Maisch) using a binary buffer system: 
A) 0.1% formic acid and B) 0.1% formic acid in ACN. The content of buffer B was raised 
from 7% to 23 % within 120 min and followed by an increase to 45% within 10 min. Then, 
within 5 min buffer B fraction was raised to 80% and held for further 5 min after which it 
was decreased to 5% within 2 min and held there for further 3 min before the next sample 
was loaded on the column. Eluted peptides were ionized by an applied voltage of 2.2 kV. 
The capillary temperature was 275°C and the S-lens RF level was set to 60. MS1 spectra 
were acquired using a resolution of 70,000 (at 200 m/z), an Automatic Gain Control (AGC) 
target of 3e6 and a maximum injection time of 20 ms in a scan range of 300–1750 Th. In 
a data dependent mode, the 10 most intense peaks were selected for isolation and 
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fragmentation in the HCD cell using normalized collision energy of 25 at an isolation 
window of 2.1 Th. Dynamic exclusion was enabled and set to 20 s. The MS/MS scan 
properties were: 17,500 resolution at 200 m/z, an AGC target of 5e5 and a maximum 
injection time of 60 ms. All label-free proteomics data sets were analyzed with the 
MaxQuant software (release 1.5.3.8). We employed the LFQ mode132 and used MaxQuant 
default settings for protein identification and LFQ quantification. All downstream 
analyzes were carried out on LFQ values with Perseus (v. 1.5.2.4)133. 
2.2.3.2 Western blot 
Cells were washed twice with PBS, then scraped from tissue culture plates and 
lysed in protein cell lysis buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 10   EDTA, 50 mM 
NaF, 1% Triton X-100, 0.1% SDS supplemented with 20 μg ml−1  Aprotinin, 2 mM sodium 
orthovanadate, 1 mM phenylmethylsulphonyl fluoride and protease inhibitor (Roche)) by 
incubating samples for 10 min on ice and homogenization through syringe needle (27G). 
Cell lysates were centrifuged at 10,000g for 10 min at 4°C and the supernatant was 
collected. Protein concentrations were determined with a standard BCA protein assay 
(Thermo Scientific). Approximately 10–20 μg of total protein were separated by SDS–
PAGE, transferred to PVDF membranes (Millipore) and subjected to immunoblotting.  
2.2.3.3 Protein immunoprecipitation for interactome analysis.  
hESCs were lysed in modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 M NaCl, 
1% IgPal, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM PMSF) supplemented with 
protease inhibitor (Roche). Lysates were centrifuged at 10,000g for 10 min at 4°C. Then, 
the supernatant was collected and incubated with HTT antibody (Cell Signaling 
Technology, #5656, 1:50) for 30 min and subsequently with 100 μl Protein A beads 
(Miltenyi) for 1 h on the overhead shaker at 4°C. As a control, the same amount of protein 
was incubated with anti-FLAG antibody (SIGMA, F7425, 1:100) in parallel. After this 
incubation, supernatants were subjected to magnetic column purification. Three washes 
were performed using wash buffer 1 (containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 
5% glycerol and 0.05% IgPal). Next, columns were washed five times with wash buffer 2 
(containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl). Then, columns were subjected to in-
column tryptic digestion containing 7.5 mM ammonium bicarbonate, 2 M urea, 1 mM DTT 
and 5 ng ml−1 trypsin. Digested peptides were eluted using two times 50 μl of elution 
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buffer 1 containing 2 M urea, 7.5 mM Ambic, and 5 mM IAA. Digests were incubated over 
night at room temperature with mild shaking in the dark. Samples were stage-tipped the 
next day for label-free quantitative proteomics and analyzed with MaxQuant software. 
The downstream analyzes were carried out on LFQ values with Perseus (v. 1.5.2.4). 
2.2.3.4 RNA sequencing.  
 
Total RNA was extracted using RNAbee (Tel-Test Inc.). Libraries were prepared 
using the TruSeq Stranded mRNA Library Prep Kit. Library preparation started with 1 μg 
total RNA. After selection (using poly-T oligo-attached magnetic beads), mRNA was 
purified and fragmented using divalent cations under elevated temperature. The RNA 
fragments underwent reverse transcription using random primers followed by second 
strand cDNA synthesis with DNA Polymerase I and RNase H. After end repair and A-
tailing, indexing adapters were ligated. The products were then purified and amplified 
(20 μl template, 14 PCR cycles) to create the final cDNA libraries. After library validation 
and quantification (Agilent 2100 Bioanalyzer), equimolar amounts of library were pooled. 
The pool was quantified by using the Peqlab KAPA Library Quantification Kit and the 
Applied Biosystems 7900HT Sequence Detection System. The pool was sequenced on an 
Illumina HiSeq 4000 sequencer with a paired- end (2x 75bp) protocol. We used the human 
genome sequence and annotation (EnsEMBL79) together with the splice-aware STAR 
read aligner134 (release 2.5.1b) to map and assemble our reference transcriptome. 
Subsequent transcriptome analyzes on differential gene and transcript abundance were 
carried out with the cufflinks package135 cuffdiff program (version 2.2.1). Transcripts 
showing a log2-fold change at a FDR < 0.05 were retained as significantly differentially 
expressed.  
2.2.3.5 Chromatin Immunoprecipitation ChIP-sequencing 
 
Cells were cross linked by adding 1% formaldehyde to the medium on the tissue 
culture dish and incubated on balancer for 10 min at RT. Cross linked cells were quenched 
with 0,125 M glycine on a balancer for 10 min at RT and then scraped and transferred to 
a 15 ml falcon on ice. Centrifugation at 1200 rpm for 5 min at 4°C and afterwards 2 
washing steps with 5 ml PBS 1x / PMSF 1 mM followed. The pellets were re-suspended 
with 5 ml lysis buffer 1 (50 mM Hepes, 140 mM NaCL, 1 mM EDTA, 10% glycerol, 0.5% 
NP-40, 0.25% TX-100 and protease inhibitor (Roche)) and rotated vertically at 4°C for 10 
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min. Cell suspensions were centrifuged at 4°C and 1350g for 5 min. The pellets were re-
suspended with 5 ml lysis buffer 2 (10 mM Tris, 200 mM NaCL, 1 mM EDTA, 0.5 mM EGTA) 
and rotated vertically at RT for 10 min. Again, cell suspensions were centrifuged at 4°C 
and 1350g for 5 min with a re-suspension step of the pellets with 1.5 ml lysis buffer 3 (10 
mM Tris, 100 mM NaCL, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-Deoxycholate, 0.5% N-
Lauroylsarcosine) and a p1000 to obtain single cells. Then, cells were sonicated at 4°C and 
centrifuged for 10 min at 16.000g at 4°C. The sonicated lysate was treated with 1% Triton 
X-100 and 75 μl were taken and stored as an input at -20°C. 750 μl were incubated with 
10 μg antibody rotating vertically ON at 4°C. The next day, magnetic Dynabeads G 
(ThermoFisher) at 10x volume of Antibody were aliquoted into a new microtube. The 
beads were washed 3 times in cold blocking solution (0,5% BSA, 1 PBS) and with the tubes 
placed on the magnetholder. 1 ml of antibody-chromatin mix were added to the beads and 
rotated vertically for at least 2 h at 4°C. Then the beads were washed 5x with cold RIPA 
wash buffer (50 mM Hepes, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-Deoxycholate) 
with the tubes placed on the magnetholder. Afterwards, the beads were washed 1x with 
1 ml TE+ 50 mM NaCl on ice and samples were centrifuged for 3 min at 950g and 4°C. 
After removing all liquid from the beads, 210 μl elution buffer (50 mM Tris, 10 mM EDTA, 
1% SDS) were added and mixed by flicking the tube. The proteins bound to the antibodies 
were eluted for 15 min at 65°C. Finally, beads were centrifuged for 1 min at 1600g at RT 
and placed on a magnetholder to settle and supernatants were transferred into a new 
tube. To reverse crosslinking, 3x volume of the elution buffer were added to the input and 
were incubated with the ChIP samples at 65°C ON. The next day, 1x volume of TE buffer 
and 0.2 mg ml-1 RNase were added and incubated for 1h at 37°C. Afterwards 0.2 mg ml-1 
Proteinase K were added and left for 2 h at 55°C to digest proteins. The DNA was phenol-
chloroform extracted at RT with 1x volume of 25:24:1 phenol-chloroform-isoamyl alcohol 
and centrifuged for 5 min, at maximum speed at RT, to separate layers, 1x volume 
chloroform were added to extract the DNA and centrifuged again. The upper layer 
containing the DNA, was transferred to a new tube for ethanol precipitation as follows: 
1/10 of NaOAc 3 M, 1 μl 20 mg ml-1 glycogen, 2x volume of ice cold ethanol were added 
on ice and incubated for 30 min at -80°C to precipitate DNA. A centrifugation at max speed 
at 4°C was performed for 30 min to pellet the DNA. Supernatants were removed and 0.5 
ml ice cold 70% ethanol were added to the pellets and centrifuged at 7500 rpm for 5 min. 
After removing the remaining ethanol, the pellets were air dried at RT and re-suspended 
in 40 μl dH2O and concentration of DNA determined. 
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2.2.3.6 Bioinformatic analysis of ChIP-sequencing 
 
ChIP-Seq data was analyzed by using QuickNGS (Next-Generation Sequencing) pipeline. 
ChIP-Seq reads was mapped to the Homo Sapiens (Ensembl database version 87) using 
BWA136. Quality check of the sequencing data were performed with FastQC (version 
0.10.1.). For peak calling used MACS2 (version 2.0.10)137. QuickNGS pipeline identifies all 
genes that are 2000 bp up- or downstream from the MACS2 peaks. The peak sequences 
are analyzed for enrichment of transcription factor binding motifs using MEME-ChIP 
(Version 4.10.0)138. The results comprise lists of significant peaks and reports for motif 
enrichment. The result was uploaded into MySQL database. Basic QC statistics and 
password-protected track hubs for the UCSC Genome Browser with direct hyperlinks for 
visualization were used. 
2.2.4 Statistics 
 
PRISM 6 software was used for statistical analysis to determine median and 
percentiles. P-values were calculated using the log-rank (Mantel–Cox) method. The P-
values refer to a single experiment. For the rest of experiments, unless stated otherwise, 
two-tailed unpaired students’t-test was used to check for statistical significance. Error 
bars represent standard error of the mean (S.E.M.). (*p<0.05 **p<0.01 ***p<0.001)  
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3 Results 
3.1 The role of HTT in epigenetic control of embryonic stem cell 
differentiation 
3.1.1 HTT interacts with the chromatin regulator ATF7IP 
 
In order to find out about the potential role of HTT as an epigenetic regulator in 
hESCs, in a first attempt we assessed its expression levels and abundance in hESCs 
compared to differentiated cells. Strikingly, we found that hESCs exhibit higher 
expression of HTT than their differentiated neuronal counterparts at both protein and 
mRNA levels (Figure 1A-B), supporting a role of HTT in hESC identity.  
To determine the protein binding partners of HTT in hESCs, we performed co-
immunoprecipitation experiments followed by a single shot label-free proteomic 
approach. We quantified approximately 2000 proteins and compared protein abundance 
in HTT antibody pulldowns with control FLAG antibody pulldowns in both hESCs and 
terminally differentiated neurons. Although HTT was the most enriched protein in both 
hESCs and neurons (Figure 1C-D), hierarchical clustering revealed a clear separation in 
HTT-interacting proteins between these cells (Figure 2). 
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Figure 1. HTT interacts with the chromatin factor ATF7IP in both hESCs and neurons. A, Western blot analysis of 
H9 hESCs and their differentiated counterparts with antibody to HTT. β-actin is the loading control. B, HTT relative 
expression to H9 hESCs represents the mean ± s.e.m. (n= 3 independent experiments). Statistical comparisons were 
made by Student’s t-test for unpaired samples. p-value: **(p< 0.01). C, Volcano plot of HTT interactome in H9 hESCs (n= 
3). –log (p-value) of a two-tailed t-test is plotted against the log2 ratio of protein label-free quantification (LFQ) values 
from co-immunoprecipitation (co-IP) experiments using HTT antibody compared to control co-IP with FLAG antibody. 
Blue coloured dots beyond the curved lines indicate significance after correction for multiple testing. D, Volcano plot of 
HTT interactome in neurons (n= 4). Red coloured dots beyond the curved lines demonstrate significance after 
correction for multiple testing. E, Scatterplot of protein enrichments in HTT co-IP from hESCs and neuronal cells. 
Significant intrinsic interactors in neurons, hESCs as well as common interactors in both cell types are indicated in red, 
blue and magenta, respectively. F, Venn diagram represents the number of specific and common co-
immunoprecipitated proteins with HTT antibody in hESCs and neurons. G, Co-immunoprecipitation with HTT and FLAG 
antibodies in H9 hESCs followed by western blot with antibodies to HTT, SETDB1 and ATF7IP. The images are 
representative of two independent experiments. 
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Immunoprecipitation of HTT itself was more effective in hESCs when compared 
with neurons (Figure 1 E), consistent with increased HTT expression in hESCs (Figure 1 
A). On the contrary, a major population of proteins specifically interacted with HTT in 
neurons, but not in hESCs (Figure 1 E-F).  
 
 
Table 8. Protein interactors of HTT in H9 hESCs. Protein label-free quantification (LFQ) values from co-
immunoprecipitation (co-IP) experiments using HTT antibody compared to control co-IP with FLAG antibody. 
(Student’s t-test, n= 3, FDR< 0.05). 
 
Whereas 102 proteins passed the criterions for significant interaction with HTT in 
neurons (Figure 1 D), only 7 proteins were significantly detected in hESCs (Figure 1 C,E 
and Table 8). Among them, NUP205 and U2AF2 were exclusively co-immunoprecipitated 
in hESCs whereas the other 5 proteins were also detected in neurons (Figure 1 F), 
including HTT itself and its known interactors F8A1139 and VCP140. In both hESCs and 
neurons, we found a novel interaction of HTT with ATF7IP (Figure 1 C-D), a factor that 
binds the H3K9 methyltransferase SETDB1 to regulate heterochromatin 
formation116,141,142–144. Notably, co-immunoprecipitation experiments followed by 
western blot indicated that HTT could form a complex with ATF7IP and SETDB1 (Figure 
1 G). 
 
Protein names T-test difference -log P-value
HTT 9.96 1.25
F8A1 7.69 1.33
NUP205 7.00 2.23
ASPSCR1 5.61 4.17
ATF7IP 5.55 1.08
VCP 5.30 2.01
U2AF2 1.76 3.42
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Figure 2.  Proteomic analysis of co-immunoprecipitation (Co-IP) experiments with HTT and control FLAG 
antibodies in H9 hESCs and neurons. Protein label-free quantification (LFQ) intensities indicating protein amounts 
are indicated by color code (red= high, blue= low abundance). Proteins (rows) and samples (columns) were clustered 
by Euclidean distance (neurons (n= 4), hESCs (n= 3). A clear separation of sample types and pulldowns was observable. 
3.1.2 Loss of HTT induces trimethylation of H3K9 in hESCs 
 
ATF7IP stimulates the H3K9 methyltransferase activity of SETDB1, facilitating 
H3K9 trimethylation and concomitant heterochromatin formation116,141. Knockdown of 
ATF7IP dramatically diminished nuclear SETDB1 levels as well as trimethylation of H3K9 
in hESCs (Figure 3 A-B), indicating that ATF7IP also regulates H3K9me3 in these cells. 
Interestingly, reduction of H3K9 trimethylation upon loss of ATF7IP did not affect the 
expression of pluripotency markers (Figure 3 C). 
Given that HTT interacted with ATF7IP (Figure 1 C-G), we assessed whether 
modulation of HTT impairs H3K9 trimethylation in hESCs. Indeed, we observed a 
dramatic increase in H3K9me3 levels upon HTT knockdown (Figure 3 D-E). Since hESCs 
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can vary in their characteristics, we analyzed an independent hESC line and obtained 
similar results (Figure 4 A-B). With the role of HTT in brain development72, we asked 
whether alterations in H3K9me3 levels of hESCs are transmitted to their NPC 
counterparts. For this purpose, we performed neural induction and found that the 
expression of the early neuroectodermal marker PAX6145 as well as other neural markers 
were triggered at the same extent in both control and HTT KD cells (Figure 5 A-C). These 
results indicate that HTT is not required for hESC commitment into NPCs. However, NPCs-
derived from HTT KD hESCs maintained high levels of H3K9me3 compared with control 
NPCs (Figure 3 F-G).  
 
Figure 3. Loss of HTT induces trimethylation of H3K9me3. A, Immunocytochemistry of H9 hESCs with antibodies 
to ATF7IP and SETDB1. Hoechst staining was used as a marker of nuclei. Scale bar represents 10 μm. B, Western blot 
analysis of H9 hESC lysates with antibodies to ATF7IP, H3K9me3, and total H3. β-actin is the loading control. C, qPCR 
analysis of pluripotency markers. Graph (relative expression to NT shRNA H9 hESCs) represents the mean ± s.e.m. of 
three independent experiments. D, Western blot analysis of H9 hESC lysates with antibodies to HTT, H3K9me3 and total 
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H3. E, Immunocytochemistry of H9 hESCs with antibody to H3K9me3. Hoechst staining was used as a marker of nuclei. 
Scale bar represents 20 μm. F, Western blot analysis of H9 NPC lysates with antibody to H3K9me3 and total H3. G, 
Immunocytochemistry of H9 NPC with antibody to H3K9me3. Hoechst staining was used as a marker of nuclei. Scale 
bar represents 20 μm. All the statistical comparisons were made by Student’s t-test for unpaired samples. P-value: 
*(P<0.05), **(P<0.01), ***(P<0.001), **** (P<0.0001). 
 
 
Figure 4. Loss of HTT induces trimethylation of H3K9me3 in H1 hESCs. A, Western blot analysis with antibody to 
HTT, H3K9me3 and total H3. β-actin is the loading control. B, Immunocytochemistry of H1 hESCs with antibody to 
H3K9me3. Hoechst staining was used as a marker of pluripotency of nuclei. Scale bar represents 20 μm.  
Loss of HTT did not affect the total levels of ATF7IP (Figure 6 A). However, loss of 
HTT changed the nuclear distribution of ATF7IP, which markedly concentrated in specific 
areas in contrast to the diffused pattern characteristic of control hESCs (Figure 6 A).  
 
Figure 5. HTT KD hESCs retain their ability to differentiate into NPCs. A, Immunocytochemistry after 10 days of 
neural differentiation assay. OCT4, PAX6, and DAPI staining were used as markers of pluripotency, neuroectodermal 
differentiation, and nuclei, respectively. Scale bar represents 20 μm. B, Western blot analysis with antibody to PAX6 in 
early NPCs (10 days after neural induction). β-actin is the loading control. C, Data represent the mean ± s.e.m. of relative 
expression levels to NT shRNA early NPCs (n= 9).  
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Notably, loss of HTT induced the interaction of ATF7IP with SETDB1 as well as 
other alterations in the interactome of ATFTIP (Figure 6 B). Taken together, these 
preliminary results indicate that HTT modulates the interaction of SETDB1 with its 
activator ATF7IP to control trimethylation of H3K9. 
 
Figure 6. HTT modulates ATF7IP and its interaction with SETDB1. A, Immunocytochemistry of H9 hESCs with 
antibody to ATF7IP. Hoechst staining was used as a marker of nuclei. Scale bar represents 10 μm. B, Co-
immunoprecipitation with ATF7IP and FLAG antibodies in H9 hESCs followed by western blot with antibodies to 
SETDB1 and ATF7IP. The images are representative of two independent experiments. 
 
3.1.3 Aberrant H3K9me3 marks upon HTT knockdown impairs induction of 
distinct neural genes 
 
Next, we asked whether the knockdown of HTT would alter the expression of 
marker proteins of pluripotency and neuronal differentiation. Knockdown of HTT did not 
impair the levels of pluripotency markers of hESCs (Figure 7 A-B). Moreover, we found no 
differences in the markers of the distinct germ layers (Figure 7 C).  
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Figure 7. Altered H3K9me3 marks upon HTT knockdown impairs the induction of distinct neural genes. A, 
Western blot analysis of H9 hESC lysates with antibodies to HTT, OCT4 and SOX2. β-actin is the loading control. B, 
Knockdown of HTT does not change the mRNA levels of pluripotency markers. Graph (relative expression to non-
targeting (NT) shRNA H9 hESCs) represents the mean ± s.e.m. (n= 9). C, qPCR analysis of ectodermal (PAX6, NES, FGF5), 
mesodermal (MSX1) and endodermal (ALB, GATA4, GATA6) germ layer markers. Graph (relative expression to NT 
shRNA hESCs) represents the mean ± s.e.m. (n= 8). E, qPCR analysis of H9 hESCs. Graph (relative expression to NT 
shRNA) represents the mean ± s.e.m. of three independent experiments with two biological replicates. F, qPCR analysis 
after 20 days of neural induction. Data (relative expression to NT shRNA cells) represent three independent 
experiments. All the statistical comparisons were made by Student’s t-test for unpaired samples. P-value: *(P<0.05), 
**(P<0.01), ***(P<0.001), **** (P<0.0001). 
 
To further assess changes induced by loss of HTT, we analyzed the proteome of 
hESCs. In quintuplicate analysis, we identified 6610 proteins, of which we quantified 4820 
in all samples. Hierarchical clustering revealed separation of HTT knockdown and NT 
samples based on global protein expression profiles (Figure 8 A). The quantitative 
analysis revealed that 186 of proteins were changed in HTT shRNA#1 hESCs as compared 
to NT control, whereas 64 of proteins were changed in HTT shRNA#2 hESCs as compared 
to NT hESCs (Figure 8 B). Correlational analysis revealed a moderate, but significant 
correlation between HTT shRNA #1 and HTT shRNA #2 KD hESC lines (Figure 8 C). To 
examine the function of these proteins altered on HTT KD, we performed 2D Gene 
Ontology (GO) enrichment (Figure 8 D).  
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Figure 8. Analysis of the proteome of HTT KD hESCs. A, Label-free quantification (LFQ) of 4820 proteins reveals 
partial separation of HTT knockdown and control non-targeting (NT) H9 hESCs (n= 5). Proteins (rows) and samples 
(columns) are clustered according to euclidean distance (red= high, blue= low abundance). B, Volcano plot of LFQ 
intensities in HTT KD hESC lines (shRNA #1 and #2) as compared to NT shRNA. The significance of a two-tailed t-test 
is plotted against the log2 fold change of LFQs. Proteins coloured in green are termed significant after correction of 
multiple testing (FDR= 0.05, s0= 1). C, Comparison of protein expression ratios in HTT shRNA #1 vs HTT shRNA #2 
hESCs. Protein changes in both conditions correlated significantly (-log(p)=14, Pearson’s correlation). Kernel density is 
color-coded. D, 2D GO enrichment for GO terms, uniprot key words and KEGG pathways. Significantly altered terms 
changed in both conditions are labelled with their name (FDR <0.05). 
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The analysis revealed that proteins related to HD were significantly enriched in the 
decreased protein population of HTT KD hESCs. Furthermore, the downregulated protein 
population was also significantly enriched for proteins involved in membrane function 
and organization (Figure 8 D). Proteins increased on HTT KD hESCs were significantly 
enriched for proteins involved in lipid biosynthesis, but also transcription, chromatin 
regulation and extracellular matrix structural constituents (Figure 8 D). Besides HTT, we 
found that other 14 (9 upregulated, 5 downregulated) proteins were significantly 
changed in both HTT KD hESC lines (Table 9). Among them, we found an increase in the 
levels of laminin subunits (i.e., LAMA1, LAMB1 and LAMC1) and nidogen-1, a protein 
tightly associated to laminin (Table 9).  
 
 
Table 9. List of proteins significantly changed in both HTT knockdown hESC lines (shRNA #1 and shRNA #2). 
Means are calculated from the log2 of LFQ values (LFQ HTT shRNA hESCs/Non-targeting shRNA hESCs). Statistical 
comparisons were made by Student’s t-test (n= 5, FDR< 0.05). Red= upregulated, blue = downregulated.  
 
Gene names Protein names
T-test difference -log P-value
HTT
shRNA #1
HTT
shRNA #2
HTT
shRNA #1
HTT
shRNA #2
SUV39H1 Histone-lysine N-
methyltransferase SUV39H1
5.07 3.92 5.87 1.47
ARHGEF11 Rho guanine nucleotide 
exchange factor 11
2.05 1.97 2.70 1.83
EML1 Echinoderm microtubule-
associated protein-like 1
1.87 1.79 3.19 2.36
TINAGL1 Tubulointerstitial nephritis 
antigen-like
1.51 1.60 2.70 1.77
LAMA1 Laminin subunit alpha-1 1.40 1.57 3.21 2.98
FOXK2 Forkhead box protein K2 0.95 0.88 1.96 1.82
LAMB1 Laminin subunit beta-1 0.82 1.26 1.68 2.43
NID1 Nidogen-1 0.77 0.99 1.93 1.96
LAMC1 Laminin subunit gamma-1 0.73 1.03 1.99 2.41
PRPS1 Ribose-phosphate 
pyrophosphokinase;Ribose-
phosphate
pyrophosphokinase 1 -0.51 -0.46 5.36 5.58
HLA-A;MHC class I 
HLA-A;HLA;HLA-
A*0226;HLA-A*02
HLA class I histocompatibility 
antigen. A-2 alpha chain;HLA
class I histocompatibility 
antigen. A-31 alpha 
chain;HLA class I 
histocompatibility antigen. A-
29 alpha chain -0.54 -0.44 3.46 2.71
GRN Granulins;Acrogranin;Paragr
anulin;Granulin-1;Granulin-
2;Granulin-3;Granulin-
4;Granulin-5;Granulin-
6;Granulin-7 -0.58 -0.68 1.72 2.00
F8A1 Factor VIII intron 22 protein -0.81 -1.45 3.19 1.93
HTT;HD Huntingtin -0.87 -1.98 2.75 3.11
TAGLN Transgelin -1.47 -0.87 4.17 2.53
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Moreover, both HTT KD hESC lines exhibit a significant increase in SUV39H1, a H3K9 
methyltransferase146,147 that can form multimeric complexes with other H3K9 methylases 
such as SETDB1148 and, therefore, could contribute to the aberrant H3K9me3 levels 
observed in HTT KD hESCs. 
 
 Although this proteomic experiment reveals moderate changes induced by loss of 
HTT in hESCs, it also presents important limitations for our study. For instance, this 
approach could be not sensitive enough to detect low abundant proteins in hESCs such as 
transcriptions factors or proteins upregulated during differentiation. We hypothesized 
that H3K9me3 repressive marks could further decrease the expression of these genes in 
hESCs or, more importantly, diminish their induction during differentiation. To test this 
hypothesis, we performed chromatin immunoprecipitation (ChIP) assays of hESCs using 
an antibody to H3K9me3. We found a >2-fold enrichment for H3K9me3 marks in 2006 
regions upon HTT knockdown. Among them, 61 contained coding regions, of which GO 
biological process term analysis indicated the strongest enrichment for factors involved 
in transcriptional regulation (Figure 9).  
 
Figure 9. Significantly enriched GO Biological Processes in ChIP experiments with H3K9me3 antibody in HTT 
KD hESCs. The 61 genes enriched for H3K9me3 in ChIP experiments comparing HTT shRNA #1 and HTT shRNA #2 H9 
hESCs with non-targeting shRNA H9 hESCs were analyzed for enriched GO Biological processes (p-value <0.05). 
 
These regulators include 4 zinc finger proteins (ZNF135, ZNF559, ZNF572, 
ZNF844), 3 transcription elongation factors (TCEB3C, TCEB3CL, TCEB3CL2) and 3 
developmental transcriptions (ASCL2, DLX3, GBX1). Besides these transcription factors, 
we found an enrichment for H3K9me3 in other genes important for nervous system 
formation, neuronal function, neurotransmission and synapse genesis/stabilization (i.e., 
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CELSR1, CPEB1149, SMC1B, ADRA2B, MRGPRX3). Dysfunctions in calcium homeostasis is 
one of the major alterations observed in HD neurons150,90. Interestingly, we have found 
H3K9me3 enrichment in genes involved in calcium metabolism such as OTOP1, ARPP21 
(an inhibitor of calmodulin-dependent enzymes in striatal neurons151) and OPRD1, which 
regulates neurotransmitter release by modulating calcium currents152. Prompted by 
these findings, we asked whether H3K9me3 marks induced by HTT knockdown results in 
decreased expression of these genes. In particular, we focused on the transcription factors 
ASCL2 and GBX1 because their important role in neural development. Notably, we did not 
observe significant changes in the expression of these genes at the hESC stage (Figure 7 
E). Given the low expression of these genes in hESCs is triggered upon neural 
differentiation (Figure 7 F), we hypothesized that H3K9me3 marks impair this induction. 
Indeed, loss of HTT in hESCs dramatically diminished their ability to induce the 
expression of ASCL2 and GBX1 during differentiation (Figure 7 F). In addition, we 
confirmed that HTT knockdown also resulted in diminished expression of other 
H3K9me3-enriched genes at the NPC stage (i.e., SMC1B, ADGRB1) (Figure 10). Altogether, 
these results suggest that HTT regulates the expression of distinct neural genes via 
modulation of H3K9me3. 
 
Figure 10. Knockdown of HTT in hESCs affects expression of SMC1B and ADGRB1 in their NPC counterparts. A, 
qPCR analysis of H9 hESCs. Graph (relative expression to non-targeting (NT) shRNA) represents the mean ± s.e.m. of 
three independent experiments with two biological replicates. B, qPCR analysis after 20 days of neural induction. Data 
(relative expression to NT shRNA cells) represent three independent experiments. All the statistical comparisons were 
made by Student’s t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), **** (P<0.0001). 
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3.1.4 Knockdown of ATF7IP rescues H3K9me3 changes induced by mHTT 
 
With the increased trimethylation of H3K9 in brain tissues of HD patients and mouse 
models111–114, we asked whether HD-iPSCs also exhibit alterations in H3K9me3 levels. 
Indeed, we found that HD-iPSCs with medium (71) and large (180) polyQ expansions have 
increased H3K9me3 levels as detected by immunofluorescence (Figure 11 A). 
 
Figure 11. Mutations in HTT reduces its interaction with ATF7IP and induces H3K9me3 levels. A, 
Immunocytochemistry of control iPSC #1, HD-iPSCs #1 (Q71) and HD-iPSCs #1 (Q180) with antibody to H3K9me3. 
Hoechst staining was used as a marker of nuclei. Scale bar represents 20 μm. B, Co-immunoprecipitation with PolyQ-
expanded HTT and total HTT antibodies in HD iPSC line #1 (Q71) followed by western blot with antibodies to PolyQ-
expanded HTT, total HTT, ATF7IP and SETDB1. The images are representative of two independent experiments. 
 
The HD-iPSC lines used in this study express one mutant copy of HTT but also one 
normal copy (Figure 11 B)153, allowing us to assess differences in the interaction of 
ATF7IP with wild-type and mHTT within the same cell. To determine these differences, 
we performed co-immunoprecipitation experiments using either an antibody against 
total HTT or polyQ-expanded HTT59. After we confirmed the later antibody only 
immunoprecipitated mHTT, we performed western blot against ATF7IP and SETDB1 
(Figure 11 B). Strikingly, we could not detect ATF7IP or SETDB1 in polyQ-expanded HTT 
pulldowns whereas total HTT pulldown showed interaction with the chromatin factor and 
the H3K9 methyltransferase (Figure 11 B), indicating that mutations in the polyQ stretch 
impairs HTT interaction with ATF7IP and SETDB1.  
 
Prompted by these findings, we examined whether loss of ATF7IP diminishes 
trimethylation of H3K9 in NPCs derived from HD-iPSCs (Figure 12 A). Indeed, we found 
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that ATF7IP knockdown is sufficient to reduce H3K9me3 levels in HD-NPCs (Figure 12 A). 
Since differentiation of HD-iPSCs generate NPCs that already present HD-related 
changes90,154, one step further was to rescue H3K9me3 levels at the pluripotent state.  
 
Figure 12. Knockdown of ATF7IP reduces H3K9me3 levels in HD-iPSCs without affecting their ability to 
differentiate into NPCs. A, 20 days after neural induction, knockdown of ATF7IP in NPCs decreases H3K9me3 levels 
as assessed by western blot experiments. The images are representative of two independent experiments. B, Western 
blot analysis of HD-iPSC line #2 (Q180) lysates with antibodies to H3K9me3 and total H3. β-actin is the loading control. 
C, Immunocytochemistry of control iPSC line #3 (Q21), HD-iPSC line #1 (Q71) and HD-iPSC line #2 (Q180) with 
antibody to H3K9me3. Hoechst staining was used as a marker of nuclei. Scale bar represents 20 μm. D, qPCR analysis 
of pluripotency (OCT4, NANOG, SOX2) and neuroectoderm (PAX6, TUBB3) markers in the indicated control and HD 
iPSC lines upon ATF7IP knockdown. Graphs (relative expression to NT shRNA) represent the mean ± s.e.m. (n= 3-4). All 
the statistical comparisons were made by Student’s t-test for unpaired samples. P-value: *(P<0.05), **(P<0.01), 
***(P<0.001), **** (P<0.0001). 
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Notably, knockdown of ATF7IP diminished H3K9me3 levels in HD-iPSCs (Figure 
12 B-C and Figure 13). However, loss of ATF7IP did not affect the expression of distinct 
pluripotency and neuroectoderm markers in iPSC lines (Figure 12 D). Moreover, ATF7IP 
knockdown did not impair the ability of HD-iPSCs to differentiate into PAX6-positive cells 
(Figure 12 E-F). Collectively, these data suggest that modulation of ATF7IP can correct 
H3K9me3 dysregulation in HD-iPSCs without affecting their ability to generate neural 
cells.  
 
 
Figure 13. Loss of ATF7IP reduces H3K9me3 levels in HD-iPSCs. Western blot analysis of HD-iPSC line #1 (Q71) 
lysates with antibodies to H3K9me3 and total H3. β-actin is the loading control. Images are representative of two 
independent experiments. 
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3.2 The role of UBE2K in epigenetic control of embryonic stem cell 
differentiation 
 
3.2.1 Loss of UBE2K impairs neurogenesis from hESCs 
 
Previously, our laboratory has discovered that hESCs have an intrinsic ubiquitin 
proteasome system when compared to differentiated cells such as neurons. For instance, 
we observed changes in the expression of multiple E3 enzymes as well as several E2 
enzymes (Table 10). Among them, we found increased levels of the E2 enzyme UBE2K. 
Previous studies reported that HTT interacts with UBE2K. Thus, we asked whether the 
high levels of UBE2K also participate in the epigenetic regulation of hESCs. 
 
 
Table 10. Quantitative proteomic analysis of E2 enzymes comparing hESCs with their NPC and neuronal 
counterparts. UBE2K decreases during neural differentiation of hESCs. We used limma’s moderated t-test to contrast 
hESCs (n= 9) versus NPCs (n= 5) and neurons (n= 6). Relative abundance differences are calculated from the log2 of 
label-free quantification (LFQ) values (LFQ NPCs/hESCs and LFQ Neurons/hESCs). Adjusted p-value (q-value) of <0.05 
is considered significant. NS= non-significant. 
 
NPCs Neurons
T-test 
difference
q-value T-test 
difference
q-value
UBE2C -1.54 <0.0001 -2.47 <0.0001
UBE2G1 -1.15 0.0005 -1.43 0.0001
UBE2K -1.04 0.0015 -1.03 0.0017
UBE2O -0.75 0.0241 -1.39 0.0002
UBE2Z -0.49 0.0164 -0.08 NS
UBE2S -0.98 NS -1.71 0.0012
UBE2V1 -0.01 NS 0.44 NS
UBE2V2 0.06 NS 0.40 0.0090
UBE2N 0.09 NS 0.04 NS
UBE2R2 0.14 NS 0.01 NS
UBE2M 0.20 NS 0.39 NS
UBE2Q1/UBE2Q2 0.28 NS 0.81 NS
UBE2I 0.83 0.0007 0.15 NS
UBE2L3 1.26 <0.0001 0.76 <0.0001
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First, we validated that the levels of UBE2K decrease during neural and terminal 
differentiation into neurons by western blot (Figure 14 A). The decrease in the protein 
amount of UBE2K correlated with a downregulation of the mRNA levels during 
differentiation (Figure 14 B).  
 
 
Figure 14. UBE2K is highly expressed in hESCs and iPSCs. A, B and E, Western blot analysis with antibody to UBE2K. 
β-actin is the loading control. B, UBE2K relative expression in NPCs and neurons compared to H9 hESCs represents the 
mean ± s.e.m. (n= 3 independent experiments). D, UBE2K relative expression in endoderm compared to H9 hESCs 
represents the mean ± s.e.m. (n= 5). F, UBE2K relative expression to HFF1 fibroblasts represents the mean ± s.e.m. (n= 
6). G, qPCR analysis of UBE2K and pluripotency markers in H9 hESCs. Graph (relative expression to non-targeting 
shRNA) represents the mean ± s.e.m. of three independent experiments with three biological replicates. H, Western blot 
analysis with antibodies to UBE2K, SOX2 and OCT4. β-actin is the loading control. I, qPCR analysis of ectodermal (PAX6, 
NES, FGF5), mesodermal (MSX1) and endodermal (ALB, GATA4, GATA6) germ layer markers. Graph (relative 
expression to NT shRNA) represents the mean ± s.e.m. of three independent experiments with three biological 
replicates. All the statistical comparisons were made by Student’s t-test for unpaired samples. P-value: *(P<0.05), 
**(P<0.01), ***(P<0.001), **** (P<0.0001).  
 
Although to a lesser extent, UBE2K also decreased during differentiation into 
either endoderm or mesoderm (Figure 14 C-D). Moreover, high levels of UBE2K were 
reprogrammed in iPSCs derived from fibroblasts (Figure 14 E-F). Given the strong 
correlation between UBE2K expression and pluripotency, we hypothesized that increased 
levels of UBE2K could be required to maintain the undifferentiated state of hESCs. To 
assess this hypothesis, we generated stable knockdown hESC lines by using two 
independent UBE2K shRNA (Figure 14 G-H). Loss of UBE2K did not result in significant 
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differences in pluripotency markers compared to control hESCs (Figure 14 G-H). 
Moreover, we measured the expression of markers of the distinct germ layers and found 
no significant changes in endoderm, mesoderm and ectoderm markers (Figure 14 I). Since 
hESC lines can vary in their characteristics, we examined an independent line and 
obtained similar results (Figure 15). 
 
 
Figure 15. Loss of UBE2K does not impair the induction of NES and SOX1 during the early stages of 
differentiation into NPCs. After 10 days of neural induction, cells were assessed by immunofluorescence with NES, 
SOX1, and Hoechst staining. Scale bar represents 20 μm.  
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Although loss of UBE2K did not significantly alter the levels of pluripotency 
markers in hESCs, another possibility is that UBE2K determines their ability to 
differentiate into distinct lineages. Given that UBE2K catalyzes the synthesis of Lys-48-
linked polyubiquitin chains targeting proteins for proteasomal degradation 123,155 and 
increased proteasome activity is required for neurogenesis from hESCs 156,157, we focused 
on the neural lineage. For this purpose, we performed neural induction and monitored 
the expression of PAX6, an early marker of neuroectodermal differentiation 91,92. After 10 
days of neural induction, PAX6 levels were triggered at the same extent in both control 
and UBE2K knockdown (KD) hESCs resulting in cultures of 100% PAX6-positive cells 
(Figure 16 A-C). We also analyzed the levels of other neural and neuronal markers and 
found no significant differences at this stage (Figure 16 C and Figure 15). These results 
indicate that UBE2K is not required for the commitment of hESCs to a neuroectoderm fate. 
However, we observed dramatic differences when we further differentiated these cells 
(20 days on neural induction treatment) to obtain NPCs with the ability to generate 
terminally differentiated neurons (Figure 16 D-G). At this stage, control NPCs decreased 
the expression of the early neural marker PAX6 whereas the levels of NPC (e.g., nestin, 
SOX1) and neuronal markers are upregulated (Figure 16 F-G). In contrast, UBE2K KD cells 
maintained high levels of PAX6 whereas the levels of neural and neuronal markers are 
significantly lower compared with control NPCs (Figure 16 D-G). Upon neuronal 
differentiation treatment, UBE2K KD cells did not develop neuronal extensions (Figure 16 
H) and showed a dramatic impairment in the expression of neuronal markers such as 
MAP2, NEFL and synaptic proteins while retaining high levels of PAX6 expression (Figure 
16 H-K). Taken together, these data suggest a critical role of UBE2K in maintaining the 
ability of hESCs to differentiate into NPCs with intact neurogenic properties. 
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Figure 16. Loss of UBE2K impairs neurogenesis from hESCs. A, After 10 days of neural induction, cells were assessed 
by immunofluorescence with OCT4, PAX6, and Hoechst staining. Scale bar represents 20 μm. B, Western blot analysis 
of NPCs after 10 days of neural induction with antibody to PAX6. β-actin is the loading control. C, qPCR analysis after 
10 days of neural induction. Graph (relative expression to NT shRNA cells) represents the mean ± s.e.m. of three 
independent experiments with three biological replicates. D, After 20 days of neural induction, cells were assessed by 
immunofluorescence with OCT4, PAX6, and Hoechst staining. Scale bar represents 40 μm. E, Western blot analysis of 
NPCs after 20 days of neural induction with antibodies to MAP2, NES, PAX6 and β-actin. F, G, qPCR analysis after 20 
days of neural induction. Graph (relative expression to NT shRNA cells) represents the mean ± s.e.m. of XX independent 
experiments with three biological replicates. H, After 3 weeks of neuronal induction, cells were assessed by 
immunofluorescence with MAP2, PAX6, and Hoechst staining. Scale bar represents 20 μm. I, Percentage of MAP2 and 
PAX6-positive cells/total nuclei after three weeks of neuronal induction (mean ± s.e.m. of two independent 
experiments, 300-400 total cells per experiment). All the statistical comparisons were made by Student’s t-test for 
unpaired samples. P-value: *(P<0.05), **(P<0.01), ***(P<0.001), **** (P<0.0001).  
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3.2.2 Knockdown of UBE2K induces trimethylation of H3K9 and impairs induction 
of neuronal genes 
 
To determine the mechanism(s) by which UBE2K impinges upon hESC function, 
we performed co-immunoprecipitation experiments followed by a single shot label-free 
proteomic approach (Table 11).  
 
 
Figure 17. UBE2K regulates trimethylation of H3K9. A, Western blot analysis of nuclear and cytosolic fractions from 
H9 hESCs with antibodies to OCT4 and UBE2K. B, Western blot analysis of H9 hESCs with antibodies to H3K9me3 and 
total histones H3. C, Immunocytochemistry of H9 hESC cultures with antibody to H3K9me3 and Hoechst staining. Scale 
bar represents 20 μm. D, After 3 weeks of neuronal induction, cells were assessed by immunofluorescence with 
H3K9me3 and Hoechst staining. Scale bar represents 20 μm. 
 
 
We observed that UBE2K, mitochondrial fission factor (MFF) and the histone H3.3 
are the most enriched proteins upon UBE2K co-immunoprecipitation (Table 11). H3.3 is 
a highly conserved histone that differs from the canonical histones H3.1/H3.2 by only four 
to five amino acid, respectively. Interestingly, H3.3 is involved in cell differentiation and 
cell reprogramming158,159. In support of a potential role of UBE2K in the nucleus, we 
detected significant amounts of this E2 enzyme in nuclear fractions of hESCs  (Figure 17 
A).  
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Table 11. Protein interactors of UBE2K in H9 hESCs. Protein label-free quantification (LFQ) from co-
immunoprecipitation (co-IP) experiments with UBE2K antibody compared to control co-IP with FLAG antibody (n=3, 
Student’s t-test, FDR< 0.05 is considered significant). 
 
With the strong interaction between UBE2K and H3.3, we asked whether loss of 
UBE2K modulates epigenetic marks of pluripotent stem cells. In hESCs, chromatin 
repressive marks such as H3K9me3 are usually reduced whereas the levels of 
transcriptional activations marks are globally increased101,106 Notably, knockdown of 
UBE2K induced a dramatic increase in the levels of H3K9me3 in two independent hESC 
lines as well as iPSCs (Figure 17 B-C). Once differentiated into NPCs, UBE2K KD cells 
maintained high levels of H3K9me3 compared with control cells (Figure 17 D). Taken 
together, these data indicate that UBE2K regulates the levels of the transcriptional 
repressive mark H3K9me3 in hESCs and this epigenetic alteration is transmitted to their 
neural counterparts. 
 
To assess whether increased H3K9me3 levels impair the expression of specific 
genes, we performed chromatin immunoprecipitation (ChIP) in UBE2K KD hESCs. We 
found a >2-fold enrichment for H3K9me3 marks in 71 genes upon UBE2K knockdown. 
Among them, GO biological process term analysis indicated the strongest enrichment for 
genes involved in transcriptional regulation (Figure 18).  
Gene names Protein names T-test difference -log P-value
MFF Mitochondrial fission factor 8.68 3.24
UBE2K Ubiquitin-conjugating enzyme E2 K 5.29 2.74
H3F3B;H3F3A;H3F3C Histone H3;Histone H3.3;Histone H3.3C 5.07 1.47
C14orf166 UPF0568 protein C14orf166 4.78 1.66
HCFC1 Host cell factor 1 4.41 2.27
DYNLT1 Dynein light chain Tctex-type 1 3.76 2.23
ATP1A1 Sodium/potassium-transporting ATPase subunit 
alpha-1
3.71 2.85
PTCD3 Pentatricopeptide repeat domain-containing protein 
3, mitochondrial
3.31 2.72
CSNK2A1;CSNK2A3 Casein kinase II subunit alpha;Casein kinase II 
subunit alpha 3
3.04 2.39
CPNE1 Copine-1 2.99 2.79
PIP4K2A;PIP4K2B Phosphatidylinositol 5-phosphate 4-kinase type-2 
alpha/beta
2.71 2.71
PLCB4 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-4
2.39 3.34
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Figure 18. Significantly enriched GO Biological Processes in UBE2K KD hESCs in ChIP experiments with 
H3K9me3 antibody. The 71 genes enriched for H3K9me3 in ChIP experiments comparing UBE2K shRNA #1 and 
UBE2K shRNA #2 H9 hESCs with non-targeting shRNA H9 hESCs were analyzed for enriched GO Biological Processes 
(p-value <0.05 is considered significant). 
 
These regulators include 7 zinc finger proteins (ZNF263, ZNF274, ZNF416, 
ZNF559, ZNF562, ZNF844, ZNF879), the transcription factor GBX1 and the bHLH 
transcription cofactor HES6. GBX1 is highly expressed in the neuroectoderm and 
modulates midbrain/forebrain formation by determining the positioning of the midbrain-
hindbrain boundary organizer in the early neural plate55. HES6 promotes neuronal 
differentiation by allowing the transcription factor ASCL1 to induce the expression of 
genes required for neurogenesis at early stages of development 160. Besides these 
transcription factors, loss of UBE2K induced an enrichment for H3K9me3 marks in 
several genes involved in nervous system formation, neuronal function, establishment of 
neuronal connections,  synapse stabilization, and neurotransmission (e.g., ADRA2B, 
CELSR1, CPEB156, KCNA3, KCNA5, KCNF1, OPRD158, PCDHB15, SMC1B, and the GABA 
receptor subunit GABRR1). Prompted by these findings, we tested whether H3K9me3 
modifications result in decreased expression of these pro-neural genes by quantitative 
analysis of the transcriptome in UBE2K KD hESCs. Integrated analysis of ChIP and 
transcriptomics data did not show significant downregulated expression of most of the 
genes enriched for H3K9me3 in UBE2K KD hESCs. Taken together, our data indicate that 
high levels of UBE2K in hESCs maintain low levels of H3K9me3 marks in key pro-neural 
and neuronal genes.  
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3.2.3 UBE2K modulates JARID2 levels  
 
To determine potential targets of UBE2K involved in the trimethylation of H3K9, 
we performed quantitative proteomics comparing control hESCs with UBE2K KD hESCs 
(Table 12). Interestingly, loss of UBE2K induced an increase in the levels of the histone 
methyltransferase regulator JARID2 and also METTL7A, a methyltransferase of unknown 
function.  
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List of proteins upregulated upon knockdown of UBE2K in hESCs 
 
 
  
Gene names Protein names 
T-test difference -log P-value 
UBE2K 
shRNA 1 
UBE2K 
shRNA 2 
UBE2K 
shRNA 1 
UBE2K 
shRNA 2 
PDIA3 Thioredoxin 3.766822433 3.537664413 1.630461609 1.526517826 
ACIN1 
Apoptotic chromatin condensation 
inducer in the nucleus 3.113811111 1.800709534 2.16746478 0.799576478 
CAMKMT 
Calmodulin-lysine N-
methyltransferase 1.810609055 1.395643234 3.519090939 2.557966309 
PTPRK;DKFZp686C22
68 
Receptor-type tyrosine-protein 
phosphatase kappa 1.649758911 1.251145172 1.519857384 1.189812485 
CHTF8 
Chromosome transmission fidelity 
protein 8 homolog isoform 2 1.510147858 0.980948257 1.386838829 0.849038968 
ITFG3 Protein ITFG3 1.507901764 1.077629471 1.917895863 1.352574137 
MTX2 Metaxin-2 1.472535706 1.199636841 1.9143298 2.299868229 
  1.15671196 0.963488007 1.337530165 1.669025503 
RTN3 Reticulon-3 1.113307571 0.349462128 1.973097302 1.425925157 
AKT2 
RAC-beta serine/threonine-protein 
kinase 1.075060272 0.823015213 1.275061416 1.19066161 
KRR1 
KRR1 small subunit processome 
component homolog 0.980365753 0.800683975 1.43367122 1.150263958 
PEX6 Peroxisome assembly factor 2 0.947927475 0.614145279 1.658016293 1.818815276 
HNRPK  0.944860077 0.994746399 2.144466584 3.701768666 
PPP1CC 
Serine/threonine-protein 
phosphatase;Serine/threonine-
protein phosphatase PP1-gamma 
catalytic subunit 0.910209656 0.740813446 4.434130041 4.19317083 
PRR12 Proline-rich protein 12 0.891211319 0.916115952 1.533050423 1.772712042 
METTL7A 
Methyltransferase-like protein 
7A 0.888065338 0.410329056 3.705815148 1.433225187 
TINAGL1 
Tubulointerstitial nephritis antigen-
like 0.850399399 1.655990982 1.410828002 1.582731679 
LAMTOR2 
Ragulator complex protein 
LAMTOR2 0.794325256 0.680993652 2.23092675 2.226474669 
ZNF423 Zinc finger protein 423 0.787024689 0.67005806 1.438159146 0.921969238 
TIPIN TIMELESS-interacting protein 0.693198013 0.903326797 2.01428658 2.025764635 
ATG4B Cysteine protease ATG4B 0.689982224 0.590264511 1.972398067 1.764654486 
SRPRB 
Signal recognition particle receptor 
subunit beta 0.670551682 0.735467911 1.910974477 2.170009455 
TWF1 Twinfilin-1 0.666596985 0.427342224 3.466383113 2.00576648 
PTPRZ1 
Receptor-type tyrosine-protein 
phosphatase zeta 0.65698967 0.482600021 2.316697561 1.575171444 
PRIM1 
DNA primase;DNA primase small 
subunit 0.63924942 0.405867386 2.609932771 1.297262912 
BANF1 
Barrier-to-autointegration 
factor;Barrier-to-autointegration 
factor, N-terminally processed 0.63624382 0.40088501 2.816604112 1.731231712 
MYO1D;DKFZp686A01
173 Unconventional myosin-Id 0.632105637 0.653863525 1.70442979 1.684702669 
WRNIP1 ATPase WRNIP1 0.615055847 0.590971756 1.639858688 1.583248395 
RPN2 
Dolichyl-
diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 0.609716034 0.47336998 1.593784272 1.293983071 
AP2S1 AP-2 complex subunit sigma 0.586634827 0.466293335 1.499416999 1.83993129 
PPFIA1 Liprin-alpha-1 0.554604721 0.476158905 2.809737533 2.499028144 
EHD4 EH domain-containing protein 4 0.54529686 0.284342194 2.78753207 1.887558689 
JARID2 Protein Jumonji 0.538499069 0.643983459 2.415416658 2.090819064 
USP47 
Ubiquitin carboxyl-terminal 
hydrolase 47 0.536531067 0.296683121 3.010269694 1.567925445 
PDS5B 
Sister chromatid cohesion protein 
PDS5 homolog B 0.511237717 0.460929871 1.775184545 2.458753426 
DPH2 
Diphthamide biosynthesis protein 
2 0.497331238 0.820111465 1.968375602 3.884416406 
QTRTD1 
Queuine tRNA-ribosyltransferase 
subunit QTRTD1 0.458888245 0.388759232 2.644654471 1.832552553 
RABEP1 
Rab GTPase-binding effector 
protein 1 0.445495987 0.549682617 1.788886809 1.796082833 
NAA38;LSM8 
N-alpha-acetyltransferase 38, 
NatC auxiliary subunit 0.39982872 0.551329803 2.235873173 3.890010684 
PPP1R14B 
Protein phosphatase 1 regulatory 
subunit 14B 0.38158226 0.381012344 2.195343025 1.719191952 
RPRC1;MAP7D1 MAP7 domain-containing protein 1 0.376734161 0.356851196 2.11082335 2.381141628 
KIAA1068;NUDCD3 NudC domain-containing protein 3 0.37326622 0.39627533 3.152229659 3.267324489 
MASTL 
Serine/threonine-protein kinase 
greatwall 0.364876556 0.264849472 2.200170848 2.276245822 
POU2F1;POU2F3;POU
2F2 
POU domain, class 2, transcription 
factor 1;POU domain, class 2, 
transcription factor 3;POU domain, 
class 2, transcription factor 2 0.349388885 0.288489151 3.30995442 2.093793691 
ISOC2 
Isochorismatase domain-
containing protein 2, mitochondrial 0.348838043 0.475136185 2.388902268 1.892604518 
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List of proteins downregulated upon knockdown of UBE2K in hESCs 
 
Table 12. Quantitative proteomic analysis of UBE2K KD hESCs. Knockdown of UBE2K induces an increase in the 
levels of JARID2 and METTL7A. Data represent the Student's t-test difference. Means are calculated from the log2 of 
label-free quantification (LFQ) values (LFQ UBE2K shRNA hESCs/Non-targeting shRNA hESCs). Statistical comparisons 
were made by Student’s t-test (n=3, FDR< 0.05 is considered significant).  
 
Gene names Protein names 
T-test difference -log P-value 
UBE2K 
shRNA 1 
UBE2K 
shRNA 2 
UBE2K 
shRNA 1 
UBE2K 
shRNA 2 
CDC42BPG 
Serine/threonine-protein kinase 
MRCK gamma -3.308805466 -3.671895218 2.313874392 2.572145401 
GUF1 
Translation factor GUF1, 
mitochondrial -2.985452271 -2.228926849 5.683319128 1.427168378 
IREB2 
Iron-responsive element-binding 
protein 2 -2.74932785 -2.22108078 1.486280326 0.961723146 
GPD1L 
Glycerol-3-phosphate 
dehydrogenase 1-like protein -2.642490005 -2.724894333 1.978762322 2.002318405 
HNRNPA2B1   -2.283238602 -1.785467529 1.536767217 1.102754473 
VSIG1 
V-set and immunoglobulin domain-
containing protein 1 -2.110469818 -2.415558243 1.521879169 1.718514194 
COL1A1 Collagen alpha-1(I) chain -1.897432709 -1.708493805 3.887163273 1.702390225 
ELOF1 
Transcription elongation factor 1 
homolog -1.801469803 -1.104278183 1.79999936 0.891784785 
CALR   -1.748747635 -1.683153152 1.10158368 1.220123527 
ARF3 ADP-ribosylation factor 3 -1.706129074 -1.226445007 2.075322275 0.897027955 
EIF4ENIF1 
Eukaryotic translation initiation 
factor 4E transporter -1.609062195 -0.896789551 1.531168942 1.000597751 
EEF1D   -1.547586441 -1.001054382 1.35970928 0.825693509 
C1orf52 UPF0690 protein C1orf52 -1.506440353 -1.041460037 1.82405246 1.090503195 
AGPAT5 
1-acyl-sn-glycerol-3-phosphate 
acyltransferase epsilon -1.483044434 -1.491923141 2.202672297 1.222544224 
SNRPA 
U1 small nuclear ribonucleoprotein 
A -1.443012238 -1.914863968 1.216235856 4.165111673 
OLFML3 Olfactomedin-like protein 3 -1.423392868 -0.385329437 6.236388008 1.90023741 
    -1.379608154 -0.822431564 2.067147219 1.75288053 
KRI1 Protein KRI1 homolog -1.342892838 -0.750530624 2.182094652 0.909809438 
SURF2 Surfeit locus protein 2 -1.283132172 -0.97299118 2.910134881 3.963727616 
TAGLN Transgelin -1.279749298 -1.79088974 2.445198055 4.801074663 
ASF1B Histone chaperone ASF1B -1.272428131 -1.816962433 1.325590561 1.796750484 
NRBF2 Nuclear receptor-binding factor 2 -1.193226242 -1.678313446 1.983198401 3.260019387 
    -1.183207321 -0.59865303 3.155417212 1.009639781 
APOL2 Apolipoprotein L2 -1.135781479 -0.492294693 1.835699686 2.21891893 
APOBEC3B 
DNA dC->dU-editing enzyme 
APOBEC-3B -1.06306076 -0.392131424 2.282506642 1.196435707 
SF3B4 Splicing factor 3B subunit 4 -1.054370117 -1.851135635 1.377491857 1.676088019 
MRPL52 
39S ribosomal protein L52, 
mitochondrial -0.972199631 -1.11235466 1.259933299 1.501125917 
UBE2K;HIP2 
Ubiquitin-conjugating enzyme E2 
K -0.942032242 -0.235050583 6.052221883 2.122918185 
GTSE1 
G2 and S phase-expressed 
protein 1 -0.92220459 -0.633312607 1.963942384 2.022792307 
BTF3   -0.90814476 -1.339248657 1.619096575 1.154610138 
GRN 
Granulins;Acrogranin;Paragranulin
;Granulin-1;Granulin-2;Granulin-3;
Granulin-4;Granulin-5;Granulin-6;
Granulin-7 -0.90234642 -0.581676102 1.9758326 1.215667468 
SERPINB9 Serpin B9 -0.89896431 -0.352035522 4.640291608 2.896273366 
MRPL30 
39S ribosomal protein L30, 
mitochondrial -0.885395813 -1.076121902 1.343190499 1.396136452 
HMGN1 
Non-histone chromosomal protein 
HMG-14 -0.861757278 -0.705495453 1.38586805 1.63800677 
LMCD1 
LIM and cysteine-rich domains 
protein 1 -0.817088699 -0.889386368 3.024417364 0.919913399 
GJA1 
Gap junction protein;Gap junction 
alpha-1 protein -0.814079285 -0.369154358 3.344818885 1.723617457 
VIL1 Villin-1 -0.805224991 -0.731871033 2.803879789 2.37242862 
RAB5C Ras-related protein Rab-5C -0.800119781 -0.295869827 1.9101014 1.479999516 
DPYSL3 
Dihydropyrimidinase-related 
protein 3 -0.769957733 -0.644638824 1.574167923 1.350460988 
MRPL48 
39S ribosomal protein L48, 
mitochondrial -0.767944717 -0.817710876 1.331264178 1.169159941 
  
6-phosphogluconate 
dehydrogenase, decarboxylating -0.734509277 -0.657603836 2.06917207 1.556442553 
ASS;ASS1 Argininosuccinate synthase -0.729299545 -0.60763092 2.973673749 2.408142227 
SLC7A5;lat1 
Large neutral amino acids 
transporter small subunit 1 -0.704777527 -0.653501511 1.887752441 2.015965765 
ANXA3 Annexin A3;Annexin -0.701567078 -0.751037216 2.773724515 3.916248612 
CCDC55;NSRP1 
Nuclear speckle splicing 
regulatory protein 1 -0.629239655 -0.801021957 1.84430775 1.543878202 
C19orf43 Uncharacterized protein C19orf43 -0.575564194 -0.444667053 2.310459425 2.376381253 
PRKCA 
Protein kinase C;Protein kinase C 
alpha type -0.573003387 -0.74417305 1.718180754 0.970319574 
TPM1   -0.551699829 -0.428111267 3.778522928 1.614132226 
LIMD2 LIM domain-containing protein 2 -0.545282745 -0.400942612 1.681931325 1.537445547 
MRPS7 
28S ribosomal protein S7, 
mitochondrial -0.54435997 -0.342670441 1.715134625 1.827136345 
DNAJC3 
DnaJ homolog subfamily C 
member 3 -0.522000504 -0.360580444 2.250784455 1.880106024 
RPL19 
Ribosomal protein L19;60S 
ribosomal protein L19 -0.513430786 -0.426737213 1.773519636 1.662895384 
SF1   -0.513362885 -0.576076126 1.630620442 1.132367133 
PC4;SUB1 
Activated RNA polymerase II 
transcriptional coactivator p15 -0.50621376 -0.447818375 3.094400122 3.076523262 
GULP1 
PTB domain-containing 
engulfment adapter protein 1 -0.50409317 -0.650629044 2.120089789 2.684650973 
LYAR 
Cell growth-regulating nucleolar 
protein -0.485778046 -0.38442688 2.012341163 1.308440452 
RPL26;KRBA2 60S ribosomal protein L26 -0.468328857 -0.380661011 1.94033114 2.190294946 
CALD1   -0.465930557 -0.502504349 2.83523892 3.597965113 
EIF1AX;EIF1AY 
Eukaryotic translation initiation 
factor 1A, X-
chromosomal;Eukaryotic 
translation initiation factor 1A, Y-
chromosomal -0.419506454 -0.319515991 2.15547511 1.344957833 
PSMD9 
26S proteasome non-ATPase 
regulatory subunit 9 -0.413750458 -0.364612961 2.295663822 1.671597156 
RPS6 40S ribosomal protein S6 -0.404511261 -0.2632164 2.20789106 1.729197619 
TPD52   -0.403290176 -0.440826416 2.288699898 2.470097197 
HLA-A 
HLA class I histocompatibility 
antigen -0.382816315 -0.420048141 2.278680423 2.376543337 
GIPC1 
PDZ domain-containing protein 
GIPC1 -0.377431488 -0.373831177 2.241864505 1.547179196 
NUDC Nuclear migration protein nudC -0.371879196 -0.368219376 3.021408182 1.562156434 
PSPH Phosphoserine phosphatase -0.348099518 -0.46913414 2.873791518 2.358554325 
RPS20 40S ribosomal protein S20 -0.342092133 -0.356018066 2.435034365 2.564622818 
EZR;EZR-ROS1 
Ezrin;Tyrosine-protein kinase 
receptor -0.308622742 -0.210961151 3.806140691 3.632891252 
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4 Discussion 
4.1 HTT 
 
The ubiquitous subcellular localization of HTT does not facilitate the definition of 
its function. Multiple roles have been described for wild-type HTT such as vesicular 
transport51,62,64,161 and mitotic spindle orientation72. Furthermore, HTT functions as a 
scaffolding protein to induce selective autophagy161. In addition, HTT modulates gene 
expression by binding numerous transcription factors and regulators such as the cAMP-
response element (CREB)-binding protein (CBP), specificity-protein 1 (SP1), neuroD1, 
p53 or the nuclear factor-kB (NF-kB)6. Loss of transcriptional function of HTT could 
contribute to explain the transcriptional dysregulation observed in postmortem HD 
brains and distinct HD mouse models6,109. 
 
In this study, we identified Activating transcription factor 7-interacting protein 1 
(ATF7IP), also known as MBD1-containing chromatin-associated factor 1 (MCAF1) or 
ATFa-associated modulator (AM), as a new interactor of HTT (Figure 1). In addition, our 
co-immunoprecipitation experiments followed by western blot indicate that HTT could 
form a complex together with ATF7IP and SETDB1 (Figure 1 G). ATF7IP regulates 
chromatin formation by binding and directing transcriptional factors to the general 
transcriptional machinery. The protein thereby impinges transcriptional regulation. 
Depending on the subcellular conditions the protein can operate either as an activator or 
a repressor116–119. The mechanism for gene silencing by ATF7IP via methylation is 
explained in the following paragraphs.  
  
ATF7IP controls methylation based transcriptional repression through interaction 
with the methyl-CpG binding domain 1 (MBD1) (hence its synonym MCAF1). The 
multifunctional nuclear protein acts as a transcriptional regulator and transcriptional 
repression domain. It embodies two conserved domains that interact with MBD1 and 
transcription factor Sp1. Like ATF7IP, SP1 can activate or repress transcription 
depending on the context. ATF7IP acts like a co-activator and enables Sp1-guided 
transcription. By modifying Sp1 on methylated promoter regions ATF7IP blocks 
transcription activity 116. 
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Histone methylation is essential for chromatin structure and function. The histone 
methyltransferase (HMTase) activity of Histone-lysine N-methyltransferase SETDB1 
(SETDB1) depends on the assistance of ATF7IP. It triggers the transformation of the 
dimethyl (H3K9me2) to the trimethyl state (H3K9me3) by increasing the turnover rate of 
the reaction, both in vitro and in vivo. The functional consequence of H3K9 trimethylation 
on the promoter region is transcriptional repression141. Moreover, ATF7IP aids in the 
gene expression of the two telomerase enzymes by specificity protein 1 (TERT) and 
interaction with SP1 in cancer cells. Knockdown of ATF7IP leads also to decreased levels 
of transcriptionally active RNA polymerase II and the general transcription factor ERCC3 
in the TERT promoter and consequently diminished telomerase activity. Interestingly, in 
naturally occurring abnormal proliferative cancer cells ATF7IP was regularly found to be 
overexpressed118. 
  
Notably, although not further studied, previous findings already indicated a link 
between HD age of onset and genetic variation within the ATF7IP gene: ATF7IP genetic 
variation correlated with age of onset in HD patients162. Together with our data, this 
suggests that ATF7IP is a potential modifier of the HD chromatin landscape in stem cells 
that determines the epigenetic changes of the disease: Knockdown of ATF7IP in hESCs 
decreased nuclear SETDB1 levels as well as trimethylation of H3K9 (Figure 3 A-B), which 
indicates the ATF7IP also regulates H3K9me3 in these cells. ATF7IP interacts with the 
H3K9 methyltransferase of SETDB1, facilitating H3K9 trimethylation and 
heterochromatin formation116,141. Moreover, ATF7IP stabilizes SETDB1 in the nucleus of 
human cell lines144. We also found that H3K9me3 levels upon HTT knockdown were 
drastically increased (Figure 3 D-E) in two independent hESC lines (Figure 4 A-B). 
Interestingly this effect was also observed when the cells were differentiated into NPCs 
(Figure 3 F-G).   
 
Among polyQ diseases exhibiting epigenetic imbalances, HD is the one most 
commonly studied. There are different classes of epigenetic mechanisms. DNA 
modifications entail methylation and hydroxymethylation, post-translational histone 
modifications entail acetylation, di- and tri-methylation, phosphorylation, ubiquitylation, 
SUMOylation and ADP ribosylation and lastly, the exchange of the histone variants H1, 
H3.3, H2A.Z, H2A.X109.  Our findings show for the first time that H3K9 is induced by loss 
of HTT. This is a novel observation that however is in a larger context of broad epigenetic 
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modulations induced by loss of HTT. The loss of HTT leads to failure of global H3K27 
trimethylation in embryoid bodies (EBs) derived from ESCs. However, H3K27 
dimethylation was unaffected in HTT null EBs.  H3K27 is a site predominantly targeted by 
PRC2 that has enzymatic activity to assist in gene silencing. Loss of HTT in embryos 
showed parallel phenotypes to those with lack of PRC2, although they were not as severe 
as in PRC2 null embryos. This shows that HTT only aids PRC2 in order to stimulate its 
methyltransferase activity, and does not work as its core component that is directly 
responsible for methylation. Specifically the polyQ region is interacting with PRC2, 
leading to more trimethylation of H3K27 with expanding polyQ tract163. In contrast, Htt 
CAG size, though changing histone H3K27me3, is prominently associated with altered 
histone H3K4me3 at 'active' loci67. 
 
Via ChIP-Seq we found 61 genes involved in transcriptional regulation (Figure 9) 
with increased H3K9 trimethylation at promoter sites. H3K9 trimethylation is a mark of 
transcriptional repression and in the stages of neuronal differentiation we found indeed 
that HTT knockdown led to reduced expression of ASCL2, GBX1 (Figure 7 D-E) and DLX3 
(Figure 10), which all 3 regulate developmental transcription. ASCL2 is a pro-neural 
factor involved in the determination of neuronal precursors of the nervous system and its 
transcription is regulated via histone modifications during neural differentiation from 
hESCs164. The homebox protein DLX3 is thought to have a role in the modulating the 
development of the ventral forebrain165. GBX1 is highly expressed in the neuroectoderm 
and regulates the positioning of the midbrain- hindbrain boundary organizer in the early 
neural plate, affecting forebrain and midbrain formation166. Furthermore, we found 
reduced expression of SMC1B, a structural maintenance protein involved in chromosome 
movements (Figure 10). SMC1B is a meiosis-specific cohesin member also has an 
important role in cellular response to DNA damage. Loss of SMC1B results in impairment 
of gene expression167. Although mutations in SMC1B have been linked to cancer cell 
formation167 and sterility in mice168, there is currently no evidence for its contribution to 
polyQ diseases. However, these findings provide potential new targets to study 
transcriptional imbalances in HD. Taken together, our results indicate that HTT is a 
modulator of H3K9me3 and thereby controls the expression of important neural genes.  
 
Neural cultures derived from HD patient-iPSCs exhibit H3K4me3 and H3K27ac 
epigenetic alterations, resulting in decreased levels of neurodevelopmental factors 
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involved in GABA signaling, axonal guidance and calcium influx90. Likewise, targeted 
mutations that expand the CAG stretch in one HTT allele is sufficient to impair H3K4me3 
marks in both mouse ESCs and their NPC counterparts67. Brain tissues of HD patients 
exhibit increased H3K9 trimethylation111–114 which led us to the hypothesis that this 
epigenetic mark could also be changed in HD-iPSCs. In our study, we indeed found that 
knockdown of ATF7IP in iPSCs derived from HD patients rescues the hypermethylation 
of H3K9, which suggests ATF7IP is a potent regulator of the epigenetic landscape. In our 
results obtained by immunofluorescence, we could observe increased H3K9me3 levels in 
two mutant HD-iPS cell lines, with either 71 or 180 polyQ repeat expansions (Figure 11 
A). Interestingly, we also found that mutations (triplet expansion) in HTT reduces its 
interaction with ATF7IP and very likely induces H3K9me3 levels (Figure 11 B). As 
mentioned before, the benefit of using HD-iPSC lines is that each cell expresses one 
mutant copy of HTT and one normal copy, as it is the case in HD-patients153. This 
enabled us to observe the different mechanisms resulting from interaction of ATF7IP 
with either the wild-type or mHTT within the same model.  
 
Interestingly, as opposed to the HTT antibody, the polyQ antibody did not 
immunoprecipitate ATF7IP and SETDB1. This clearly demonstrates that normal HTT 
function is necessary to promote interaction with ATF7IP and SETDB1 and thereby 
regulate trimethylation of H3K9. The underlying reason for this could be manifold: One 
explanation could be that polyQ regions of different lengths can present different 
conformations58 and therefore it is likely that the specific epitopes recognizing ATF7IP 
and SETDB1 are not accessible in mHTT. Furthermore, we already know that mHTT is 
cleaved by proteases and that its C-terminal part is released into the nucleus, and also that 
HTT forms inclusion bodies upon which the C-terminal domain changes its conformation. 
This shows the possibility that interaction between ATF7IP and SETDB1 and HTT takes 
place on this site, whereas the polyQ antibody binds to the C-terminal domain, occluding 
the two interactors seen with anti-total HTT. However, this does not contradict our 
observation that loss of normal HTT supports the interaction between ATF7IP and 
SETDB1 to increase H3K9me3. Notably, we found that another H3K9 methyltransferase, 
called SUV39H1, which is known to form a complex with SETDB1, was significantly 
increased upon loss of HTT in hESCs. 
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 In this study we also demonstrate that ATF7IP knockdown decreases H3K9 
trimethylation in HD-IPSCs (Figure 12 B-C and Figure 13) and in HD-NPCs (Figure 12 A). 
Our data show that ATF7IP knockdown can rescue the H3K9 trimethylation HD-iPSCs. 
Notably, knockdown of ATF7IP does not influence the neuronal differentiation capacity 
in these cells. In this study, we did not analyze the effect of HTT on histone acetylation, a 
major regulator of the epigenetic landscape. Histone acetylation is associated with a 
relaxed chromatin conformation, which allows access of transcription factors and is 
regulated by the histone (or lysine) acetyltransferase (KAT) and the histone deacetylase 
family (HDAC). The CREB-binding protein (CBP) with KAT activity was found in 
intracellular inclusions in postmortem tissues from HD patients, animal model brains and 
in vitro and presented the first known histone acetylation dysregulation related to 
HD169,170. Since this initial finding many studies proved dysfunctional histone acetylation 
in various HD models including neuronal cells from HD Patients171. Surprisingly, some 
studies showed a global decrease in histone acetylation172,173, while others presented 
hypoacetylation merely on promoter regions leading to transcriptional 
downregulation174,175. However, despite of more than a decade of research, the exact 
mechanism of how CBP and histone acetylation contribute to neurodegeneration is 
unknown176. 
 
It should be noted that we found 102 significant interactors of HTT in neurons and 
only 7 proteins in hESCs (Figure 1 C, E and Table 8). Among the 7 interactors NUP205 and 
U2AF2 were exclusively co-immunoprecipitated in hESCs whereas the other 5 proteins 
were also detected in neurons (Figure 1 F).  NUP205 is involved in nuclear transport177, 
whereas U2AF2 is a spliceosome-associated protein controlling RNA polymerase 
activity178.  Since these two interactors are located in the nucleus, this indicates that in 
hESCs the role of HTT is related to nuclear mechanisms and suggests further modes of 
regulation of HTT on the phenotype in hESCs. 
 
4.2 UBE2K 
 
We performed a neural induction experiment in control and UBE2K knockdown 
hESCs and found that UBE2K knockdown disables the ability of the cells to differentiate 
into NPCs with intact neurogenic properties. The dramatic effect started after 20 days of 
neural induction. In contrast to the control cells, UBE2K KD NPCs showed high levels of 
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the early neural marker PAX6 and decreased levels of neural and neuronal markers 
(Figure 16 D-G). Moreover, when differentiated to neurons, UBE2K KD cells did not show 
neuronal extensions (Figure 16 H).  The neuronal markers (MAP2, NEFL) were decreased 
compared to control neurons and PAX6 levels remained high (Figure 16 H-K). 
Co-immunoprecipitation experiments followed by a single shot label-free proteomic 
approach revealed UBE2K, mitochondrial fission factor (MFF) and the histone H3.3 as 
most enriched proteins (Table 11). H3.3 is involved in cell differentiation and cell 
reprogramming158,159, which suggests a role of UBE2K in the nucleus. In line with this 
assumption, we found tremendous amounts of UBE2K in nuclear fractions of hESCs 
(Figure 17 A).  Strikingly, upon UBE2K knockdown, we observed also increased H3K9 
trimethylation. This effect was consistent in two independent hESC lines as well as iPSCs 
(Figure 17 B-C). Also, upon differentiation into NPCs, high levels of H3K9me3 were 
maintained in the UBE2K knockdown cells (Figure 17 D). This indicates that UBE2K 
regulates the levels of H3K9me3 in hESCs and their neural counterparts, and that loss of 
UBE2K leads to transcriptional repression of distinct genes. Particularly, the lack of MAP2, 
NEFL and other genes playing a role in the development and identity of NPCs and neurons 
(Figure 16 H-K), can be associated with the observed histone modifications. After 
performing ChIP-seq using UBE2K KD hESCs we found 71 genes presenting H3K9me3 
marks with strongest enrichment for genes involved in transcriptional regulation (Figure 
18). 
 
Remarkably, many genes with high enrichment for H3K9me3 marks were involved 
neuronal processes such as the formation of the nervous system, neuronal function and 
establishment of neuronal connections, supporting our results with disturbed 
differentiation into NPCs and neurons. These genes include ADRA2B, CELSR1, SMC1B, and 
the GABA receptor subunit GABRR1. In conclusion, our data indicate that loss of UBE2K 
induces changes in the H3K9me3 landscape of hESCs impairing the induction of key 
neuronal factors.  
 
When we compared control hESCs with UBE2K KD hESCs via quantitative 
proteomics we found increased levels of the histone methyltransferase regulator JARID2 
and also METTL7A, a methyltransferase of unknown function in UBE2K knockdown cells 
(Table 12). Jarid2 is required for differentiation of mouse ESCs and its inhibition leads to 
a reduction of H3K27me3 by regulating the PRC2 complex108. Furthermore, Jarid2 
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activates trimethylation of H3K9 via specific interaction with the histone H3K9 
methyltransferase SETDB1 during heart development179.  This suggests that further 
interplay of epigenetic and non-epigenetic mechanisms, is potentially modified by Ube2k. 
This requires further studies and is currently under investigation.  
 
4.3 Conclusion and the missing link between HTT and UBE2K 
 
In this study, we analyzed the effect of HTT and UBE2K knockdown on the 
epigenetic landscape of hESCs and HD-patient derived IPSCs. Consistent with previous 
studies, we discovered a strong modulation of the epigenetic landscape in these cells upon 
knockdown of both HTT and UBE2K. Particularly, promoter sites showed increased 
methylation by H3K9me3, representing transcriptional repression of these genes.  
 
For the first time, we identified ATF7IP as a novel interactor of HTT and found 
increased trimethylation of H3K9 induced upon loss of HTT in hESCs and HD-IPSCs and 
their neuronally differentiated counterparts. Markedly, the genes most affected were 
involved in neuronal functions, particularly important for the correct differentiation into 
NPCs and neurons. 
 
Moreover, the H3K9 methyltransferase SETDB1, a known interactor of ATF7IP, was 
decreased upon ATF7IP knockdown in hESCs. This indicates that ATF7IP is indeed a 
modulator of the chromatin landscape in hESCs and HD-IPSCs and thereby maintains 
proper transcriptional induction of genes. Since loss of HTT promotes the interaction of 
ATF7IP with SETDB1, HTT very likely regulates the interaction of SETDB1 with its 
activator ATF7IP to control trimethylation of H3K9. 
 
Among the transcriptional regulators that we identified via ChIP-seq in UBE2K KD 
cells, we found the bHLH transcription cofactor HES6. As mentioned in the results, HES6 
facilitates the transcription factor ASCL1 to induce the expression of important genes for 
neurogenesis at the early stages of development160. Remarkably, we found ASCL1 not only 
exhibiting enriched H3K9me3 marks on its promoter in HTT KD cells, but could also verify 
its decreased expression in NPCs on mRNA level.  
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Although previously found and confirmed as HTT interactor, we were not able to 
copurify UBE2K together with HTT: This could suggest that the interaction could be 
transient and could be associated with direct degradation of the HTT protein by UBE2K 
and associated E3 ligases. Also, it might play a role only in specific cell types, organelles 
or settings of hESCs. A study showed for example that the polyQ domain of normal HTT 
can present different conformations depending on its subcellular location58. 
 
The phenotype of UBE2K knockdown of neural differentiation is much more 
prominent as compared to HTT, and could be mediated by an increase of the histone 
methyltransferase regulator JARID2, which in turn regulates PRC2 in mice ESCs and   
promotes H3K9 trimethylation via interaction with methyltransferase SETDB1. As 
mentioned before, HTT facilitates PRC2 to stimulate its methyltransferase activity. 
Therefore, UBE2K and HTT are responsible for balancing epigenetic function and 
determining hESC fate, and PRC2 could be a common node between the two proteins that 
requires further investigation. These studies are currently underway. Interference with 
these mechanisms and the further characterization in models of disease may help to find 
novel therapies for human neurodegenerative diseases. 
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